Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Mar. 31, 2015 | Jul. 14, 2015 | Sep. 30, 2014 | |
Document And Entity Information | |||
Entity Registrant Name | Rich Pharmaceuticals, Inc. | ||
Entity Central Index Key | 1,504,389 | ||
Document Type | POS AM | ||
Document Period End Date | Mar. 31, 2015 | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --03-31 | ||
Is Entity a Well-known Seasoned Issuer? | No | ||
Is Entity a Voluntary Filer? | No | ||
Is Entity's Reporting Status Current? | No | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Public Float | $ 12,000,000 | ||
Entity Common Stock, Shares Outstanding | 3,097,091,736 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2,015 |
Balance Sheets
Balance Sheets - USD ($) | Jun. 30, 2015 | Mar. 31, 2015 | Mar. 31, 2014 |
Current Assets | |||
Cash and equivalents | $ 90 | $ 15,892 | $ 12,387 |
Prepaid expenses | 4,835 | 7,578 | 1,561 |
Total Current Assets | 4,925 | 23,470 | 13,948 |
Property and equipment, net | 670 | 788 | 1,261 |
TOTAL ASSETS | 5,595 | 24,258 | 15,209 |
Current Liabilities | |||
Accounts payable | 915,575 | 910,272 | 180,672 |
Accrued expenses | 246,415 | 200,891 | 451,290 |
Due to related parties | 6,141 | 6,067 | 36,000 |
Stock deposits | 0 | 147,050 | |
Convertible notes payable, net of debt discount | 254,415 | 402,131 | 37,500 |
Derivative liabilities | 226,408 | 139,983 | 0 |
Total Current Liabilities | 1,648,954 | 1,659,344 | 852,512 |
Long-term Liabilities | |||
Convertible notes payable, net of debt discount | 4,914 | 6,080 | 0 |
Derivative liabilities | 109,035 | 77,775 | 0 |
Total Long-term Liabilities | 113,949 | 83,855 | 0 |
Total Liabilities | 1,762,903 | 1,743,199 | 852,512 |
Stockholders Deficit | |||
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively | 6,000 | 6,000 | 6,000 |
Common stock, $.001 par value, 37,503,000,000 shares authorized, 1,541,083,957 and 414,411,438 shares issued and outstanding, respectively | 3,245,335 | 1,541,083 | 414,411 |
Additional paid-in capital | 3,074,080 | 4,168,956 | 2,043,690 |
Accumulated deficit | (8,082,723) | (7,434,980) | (3,301,404) |
Total Stockholders Deficit | (1,757,308) | (1,718,941) | (837,303) |
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT | $ 5,595 | $ 24,258 | $ 15,209 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - USD ($) | Jun. 30, 2015 | Mar. 31, 2015 | Mar. 31, 2014 |
Statement of Financial Position [Abstract] | |||
Common Stock, Par Value | $ 0.001 | $ .001 | $ .001 |
Common Stock, Shares Authorized | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 |
Common Stock, Issued | 3,245,337,213 | 1,541,083,957 | 414,411,438 |
Preferred Stock, Par Value | $ 0.001 | $ .001 | $ .001 |
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 | 10,000,000 |
Preferred Stock, Issued | 6,000,000 | 6,000,000 | 6,000,000 |
Accumulated Amortization of intangible assets |
Statements of Operations
Statements of Operations - USD ($) | 3 Months Ended | 12 Months Ended | ||
Jun. 30, 2015 | Jun. 30, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Income Statement [Abstract] | ||||
REVENUES | $ 0 | $ 0 | ||
OPERATING EXPENSES | ||||
Consulting expenses | $ 6,000 | $ 80,000 | 200,925 | 335,000 |
Office expenses | 20,753 | 22,838 | 97,821 | 39,569 |
Depreciation expense | 118 | 118 | 473 | 158 |
Wages and taxes | 91,723 | 151,079 | 727,458 | 291,358 |
Professional fees | 65,947 | 125,879 | 1,339,623 | 115,304 |
Regulatory fees | 1,669 | $ 1,065 | 52,496 | 37,591 |
Research and development | 7,000 | 165,371 | 123,802 | |
Stock-based compensation | 130,091 | $ 120,293 | 866,128 | 1,869,273 |
Impairment of intangible asset | 82,120 | 168,973 | ||
Travel, meals and entertainment | 2,612 | 16,937 | 74,010 | 23,567 |
TOTAL OPERATING EXPENSES | 325,913 | 518,209 | 3,606,425 | 3,004,595 |
LOSS FROM OPERATIONS | (325,913) | $ (518,209) | (3,606,425) | (3,004,595) |
OTHER INCOME (EXPENSE) | ||||
Amortization of debt discount | (165,629) | (504,269) | 0 | |
Change in value of derivative liability | 48,413 | 1,867,621 | 0 | |
Derivative expense | $ 191,844 | (1,809,914) | 0 | |
Forgiveness of debt | 6,009 | 0 | ||
Interest expense | $ (12,696) | $ (2,249) | (56,531) | (342) |
Interest expense, related party | $ (74) | (67) | 0 | |
Loss on share issuance | 30,000 | 0 | ||
Other Income Total | $ (2,249) | (527,151) | (342) | |
LOSS BEFORE PROVISION FOR INCOME TAXES | $ (647,743) | $ (520,458) | (4,133,576) | (3,004,937) |
PROVISION FOR INCOME TAXES | 0 | 0 | ||
NET LOSS | $ (647,743) | $ (520,458) | $ (4,133,576) | $ (3,004,937) |
NET LOSS PER SHARE: BASIC AND DILUTED | $ 0 | $ 0 | $ (0.01) | $ 0 |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED | 2,125,788,108 | 417,091,310 | 633,180,343 | 615,222,893 |
Shareholders Equity
Shareholders Equity - USD ($) | Preferred Stock | Common Stock | Additional Paid-In Capital | Accumulated Deficit During the Development Stage | Total |
Beginning balance, shares at Mar. 31, 2013 | 1,093,837,500 | ||||
Beginning balance, amount at Mar. 31, 2013 | $ 2,625 | $ 49,875 | $ (81,930) | $ (29,430) | |
Stock issued for intangible assets, shares | 6,000,000 | 82,767,038 | |||
Stock issued for intangible assets, amount | $ 6,000 | $ 199 | 117,774 | 123,973 | |
Shares cancellation, shares | (762,776,434) | ||||
Shares cancellation, amount | $ (1,831) | 1,831 | |||
Forgiveness of shareholder debt | 28,818 | 28,818 | |||
Stock split - 416.7 to 1 | $ 412,835 | (198,298) | (214,537) | ||
Stock options granted for services | 663,307 | 663,307 | |||
Stock and warrants issued for cash, shares | 583,334 | ||||
Stock and warrants issued for cash, amount | $ 583 | $ 174,417 | $ 175,000 | ||
Stock options granted for services, shares | 23,825 | 23,825 | |||
Stock options granted for services, amount | $ 1,182,141 | $ 1,182,141 | |||
Stock issued for services, amount | 0 | ||||
Net loss | (3,004,937) | (3,004,937) | |||
Ending balance, shares at Mar. 31, 2014 | 6,000,000 | 414,411,438 | |||
Ending balance, amount at Mar. 31, 2014 | $ 6,000 | $ 414,411 | 2,043,690 | (3,301,404) | (837,303) |
Issuance of common stock for cash, shares | 79,961,892 | ||||
Issuance of common stock for cash, amount | $ 79,962 | 140,038 | 220,000 | ||
Stock issued for intangible assets, shares | 220,792,028 | ||||
Stock issued for intangible assets, amount | $ 220,792 | 7,683,563 | 7,904,355 | ||
Deemed dividend for intangibles | (7,822,235) | (7,822,235) | |||
Stock options granted for services | 815,680 | 815,680 | |||
Stock and warrants issued for cash, shares | 2,483,334 | ||||
Stock and warrants issued for cash, amount | $ 2,483 | 337,517 | 340,000 | ||
Stock issued for services, shares | 16,000,000 | ||||
Stock issued for services, amount | $ 16,000 | 780,050 | 796,050 | ||
Stock issued for stock deposits, shares | 1,469,000 | ||||
Stock issued for stock deposits, amount | $ 1,469 | 145,581 | 147,050 | ||
Stock issued for debt conversion, shares | 805,966,265 | ||||
Stock issued for debt conversion, amount | $ 805,966 | (306,280) | 499,686 | ||
Derivative liability closed to APIC | 300,904 | 300,904 | |||
Stock option modification | 50,448 | 50,448 | |||
Net loss | (4,133,576) | (4,133,576) | |||
Ending balance, shares at Mar. 31, 2015 | 6,000,000 | 1,541,083,957 | |||
Ending balance, amount at Mar. 31, 2015 | $ 6,000 | $ 1,541,083 | $ 4,168,956 | $ (7,434,980) | (1,718,941) |
Stock issued for services, amount | 796,050 | ||||
Net loss | (647,743) | ||||
Ending balance, amount at Jun. 30, 2015 | $ (1,757,308) |
Shareholders Equity (Parentheti
Shareholders Equity (Parenthetical) | 12 Months Ended |
Mar. 31, 2015 | |
Statement of Stockholders' Equity [Abstract] | |
Forward Split | 416.7 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) | 3 Months Ended | 12 Months Ended | ||
Jun. 30, 2015 | Jun. 30, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
Net loss for the year | $ (647,743) | $ (520,458) | $ (4,133,576) | $ (3,004,937) |
Adjustments to reconcile net loss to net cash used in operating activities | ||||
Depreciation expense | 118 | $ 118 | 473 | 158 |
Amortization of debt discount | 165,629 | 504,269 | 0 | |
Change in value of derivative liability | (48,413) | (1,867,621) | 0 | |
Derivative expense | $ 191,844 | (1,809,914) | 0 | |
Forgiveness of debt | $ (6,009) | $ 0 | ||
Loss on share issuance | $ (30,000) | $ 0 | ||
Impairment of intangible asset | $ 82,120 | $ 168,973 | ||
Stock issued for services | $ 796,050 | 796,050 | 0 | |
Stock-based compensation | 130,091 | $ 120,293 | 866,128 | 1,869,273 |
Changes in operating assets and liabilities: | ||||
Increase in prepaid expenses | (100,000) | 2,743 | (6,017) | (1,561) |
Increase in accounts payable | 67,692 | 5,303 | 729,600 | 173,972 |
Increase in bank overdraft | 1,863 | 0 | ||
Increase (decrease) in accrued expenses | 78,605 | 45,524 | (250,399) | 451,290 |
Net Cash Used by Operating Activities | (351,887) | (141,645) | (1,445,068) | (342,832) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
Acquisition of fixed assets | 0 | (1,419) | ||
Acquisition of intangible assets | 0 | (45,000) | ||
Net Cash Used by Investing Activities | 0 | (46,419) | ||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
Loans and interest received (repaid) from/to related parties | (31,000) | 74 | (29,933) | 40,500 |
Proceeds from stock deposits | 0 | 147,500 | ||
Proceeds from sale of common stock and stock warrants | 275,000 | 29,462 | 560,000 | 175,000 |
Proceeds from the issuance of convertible note payable | 95,500 | 96,307 | 918,506 | 37,500 |
Net Cash Provided by Financing Activities | 339,500 | 125,843 | 1,448,573 | 400,050 |
Net Increase in Cash and Cash Equivalents | (12,387) | (15,802) | 3,505 | 10,799 |
Cash and cash equivalents, beginning of period | $ 12,387 | 15,892 | 15,892 | 1,588 |
Cash and cash equivalents, end of period | $ 90 | 12,387 | 15,892 | |
SUPPLEMENTAL CASH FLOW INFORMATION: | ||||
Interest paid | 0 | 342 | ||
Income taxes paid | 0 | 0 | ||
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION: | ||||
Stock deposits reclassified as common stock and stock warrants | $ 147,050 | 147,050 | 0 | |
Original issue and debt discounts recorded on notes payable | $ 11,531 | 612,827 | 0 | |
Common stock issued for accrued expenses | $ 300,000 | |||
Acquisition of intangibles for stock | 123,973 | 82,120 | 123,973 | |
Debt and interest converted to common stock and contributed capital | $ 499,825 | $ 499,825 | $ 499,686 | $ 28,818 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Accounting Policies [Abstract] | ||
Summary of Significant Accounting Policies | Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 531,292,500 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 500,255,434 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At June 30, 2015 and March 31, 2015 the Company had $90 and $15,892, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015, as filed with the U.S. Securities and Exchange Commission. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company acquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at June 30, 2015 and 2014. As of June 30, 2015, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 390,004,800 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 19,750,000 stock options to officers, directors, employees and consultants. During the period ended June 30, 2015, the Company granted 204,000,250 stock options to officers, directors, employees and consultants. On January 12, 2015, the Company modified the exercise price on all 67,253,280 outstanding stock options to $0.0017. However, on April 6, 2015, the Company again modified the exercise price on all outstanding stock options to $0.0008 per share. Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow. | Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 531,292,500 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 500,255,434 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2015 and 2014 the Company had $15,892 and $12,387, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company aquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at March 31, 2015 and 2014. As of March 31, 2015, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow. |
Property and equipment
Property and equipment | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Property, Plant and Equipment [Abstract] | ||
Property and equipment | Property and equipment, recorded at cost, consisted of the following as of June 30, 2015 and March 31, 2015: June 30, 2015 March 31, 2015 Computer equipment $ 1,419 $ 1,419 Less: accumulated depreciation (749 ) (631 ) Property and equipment, net $ 670 $ 788 The useful life of the computer equipment is 3 years. Depreciation expense was $118 and $473 for the periods ended June 30, 2015 and March 31, 2015, respectively . | Property and equipment, recorded at cost, consisted of the following as of March 31, 2015 and 2014: 2015 2014 Computer equipment $ 1,419 $ 1,419 Less: accumulated depreciation (631 ) (158 ) Property and equipment, net $ 788 $ 1,261 The useful life of the computer equipment is 3 years. Depreciation expense was $473 and $158 for the years ended March 31, 2015 and 2014, respectively . |
Intangible Assets
Intangible Assets | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Intangible Assets | On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. | On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. |
Accrued Expenses
Accrued Expenses | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Payables and Accruals [Abstract] | ||
Accrued Expenses | Accrued expenses consisted of the following as of June 30, 2015 and March 31, 2015: June 30, 2015 March 31, 2015 Wages and taxes 227,253 175,357 Accrued interest 19,162 25,534 Consulting - - Total accrued expenses $ 246,415 $ 200,891 | Accrued expenses consisted of the following as of March 31, 2015 and 2014: 2015 2014 Wages and taxes 175,357 151,290 Accrued interest 25,534 0 Consulting 0 300,000 Total accrued expenses $ 200,891 $ 451,290 The Company amended a consulting agreement on May 7, 2014, to grant 2,500,000 shares to a consultant for work performed through March 31, 2014. The shares were valued on the grant date at $300,000 and that amount had been accrued as of March 31, 2014. |
Related Party Debt and Transact
Related Party Debt and Transactions | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Related Party Transactions [Abstract] | ||
Related Party Debt and Transactions | On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with its boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. During the year ended March 31, 2015 and 2014, the Company received loans from companies controlled by its new CEO or shareholders totaling $5,000 and $36,000, respectively. The loans are unsecured, non-interest bearing with no specific terms of repayment. The Company repaid all $41,000 of the loans during the year ended March 31, 2015. Also during the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. The loan is unsecured and bears 8% interest. The total due was $6,000 as of June 30, 2015. Interest accrued on the 2015 note as of June 30, 2015 was $141. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 3,000,240 shares of common stock at an exercise price of $0.02 per share. The CEO earned $68,751 and $75,711 for the three months ended June 30, 2015 and 2014 (respectively) as a result of this agreement, of which, $192,113 and $154,062 is included in accrued as of June 30, 2015 and March 31, 2015. | On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with its boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. During the year ended March 31, 2015 and 2014, the Company received loans from companies controlled by its new CEO or shareholders totaling $5,000 and $36,000, respectively. The loans are unsecured, non-interest bearing with no specific terms of repayment. The Company repaid all $41,000 of the loans during the year ended March 31, 2015. Also during the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. The loan is unsecured and bears 8% interest. The total due was $6,000 as of March 31, 2015. Interest accrued on the 2015 note for the year ended March 31, 2015 was $67. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 3,000,240 shares of common stock at an exercise price of $0.02 per share. The CEO earned $275,000 and $229,167 for the years ended March 31, 2015 and 2014 (respectively) as a result of this agreement, of which, $154,062 and $129,717 has been accrued as of March 31, 2015 and 2014. |
Stock Deposits
Stock Deposits | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Notes to Financial Statements | ||
Stock Deposits | The Company received deposits for future stock purchases during the year ended March 31, 2014 totaling $147,050. The Company signed subscription agreements with four investors on June 16, 2014 to grant 1,469,000 shares of common stock in exchange for the deposits. The remaining balance as of March 31, 2015 is $0. | The Company received deposits for future stock purchases during the year ended March 31, 2014 totaling $147,050. The Company signed subscription agreements with four investors on June 16, 2014 to grant 1,469,000 shares of common stock in exchange for the deposits. The remaining balance as of March 31, 2015 is $0. |
Convertible Note Payable
Convertible Note Payable | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Debt Disclosure [Abstract] | ||
Convertible Note Payable | On March 11, 2014, the Company issued a convertible promissory note in the amount of $37,500. The note is due on December 13, 2014 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $37,500 of principal and $1,500 of interest into 2,159,271 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On April 8, 2014, the Company issued a convertible note payable in the amount of $53,000. The note bears 8% interest and is due on January 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date . On May 21, 2014, the Company issued a convertible note payable in the amount of $42,500. The note bears 8% interest and is due on February 23, 2015. The note is currently in default. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $42,500 of principal and $1,700 of interest into 15,252,347 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $3,380. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $66,780 of principal and $2,850 of interest into 121,442,490 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $58,300 of principal and $2,527 of interest into 131,091,236 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 140,370,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $1,067 as of June 30, 2015. On August 19, 2014, the Company issued a convertible note payable in the amount of $57,895 including an original issue discount of $2,895. The note bears 12% interest and is due on August 19, 2016. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $57,895 of principal and $14,035 of interest (including a $10,000 penalty) into 179,825,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 18,181,818 shares of common stock leaving a remaining balance of $54,500. During the period ending June 30, 2015 the note holder converted $54,500 in principal and $8,240 in accrued interest into 187,959,744 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2015. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 70,000,000 common shares leaving a remaining balance of $29,800. During the period ending June 30, 2015 the note holder converted $29,800 in principal and $2,158 in accrued interest into 86,467,222 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2015. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending June 30, 2015 the note holder converted $33,000 in principal and $1,320 in accrued interest into 78,000,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2015. On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date . On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending June 30, 2015 the note holder converted $35,980 in principal into 281,363,421 shares of common stock leaving a remaining balance of $7,020. Accrued interest was $1,968 as of June 30, 2015. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending June 30, 2015 the note holder converted $21,852 in principal into 246,700,000 shares of common stock leaving a remaining balance of $11,481. Accrued interest was $4,914 as of June 30, 2015. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended June 30, 2015 is $1,244 . On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended June 30, 2015 is $1,716. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending June 30, 2015 the note holder converted $18,294 in principal and $755 in accrued interest into 331,318,989 shares of common stock leaving a remaining balance of $34,500. Accrued interest was $1,006 as of June 30, 2015. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on December 9, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 121,555,062 common shares leaving a remaining balance of $1,898. During the period ending June 30, 2015 the note holder converted $1,898 in principal and $20 in accrued interest into 5,300,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of June 30, 2015. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. | On March 11, 2014, the Company issued a convertible promissory note in the amount of $37,500. The note is due on December 13, 2014 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $37,500 of principal and $1,500 of interest into 2,159,271 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On April 8, 2014, the Company issued a convertible note payable in the amount of $53,000. The note bears 8% interest and is due on January 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date . On May 21, 2014, the Company issued a convertible note payable in the amount of $42,500. The note bears 8% interest and is due on February 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $42,500 of principal and $1,700 of interest into 15,252,347 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $3,380. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $66,780 of principal and $2,850 of interest into 121,442,490 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $58,300 of principal and $2,527 of interest into 131,091,236 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 140,370,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $1,067 as of March 31, 2015. On August 19, 2014, the Company issued a convertible note payable in the amount of $57,895 including an original issue discount of $2,895. The note bears 12% interest and is due on August 19, 2016. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $57,895 of principal and $14,035 of interest (including a $10,000 penalty) into 179,825,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 18,181,818 shares of common stock leaving a remaining balance of $54,500. Accrued interest was $7,740 as of March 31, 2015. The loan has an unamortized original issue discount of $2,523 as of March 31, 2015. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. On March 10, 2015 the note holder converted $25,200 of the principle into 70,000,000 common shares leaving a remaining balance of $29,800. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended March 31, 2015 is $1,273. On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended March 31, 2015 is $2,622. On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended March 31, 2015 is $1,188. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended March 31, 2015 is $586. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended March 31, 2015 is $639. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on December 9, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 121,555,062 common shares leaving a remaining balance of $1,898. |
Derivative Liabilities
Derivative Liabilities | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Notes to Financial Statements | ||
Derivative Liabilities | In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the years ending March 31, 2015 and 2016: $37,500 note dated March 11, 2014; $53,000 note dated April 8, 2014; $42,500 note dated May 21, 2014; $55,000 note dated September 23, 2014; $66,780 note dated August 14, 2014; $58,300 note dated August 14, 2014; $64,500 note dated September 18, 2014; $58,300 note dated March 2, 2015; $61,111 note dated August 13, 2014; $57,895 note dated August 19, 2014; $33,333 note dated December 16, 2014; $27,778 note dated February 25, 2015; $33,000 noted dated October 6, 2014; $55,000 note dated November 6, 2014; $43,000 note dated November 25, 2014; $68,900 note dated May 5, 2015; $16,500 note dated May 27, 2015. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended June 30, 2015, the Company recorded a total change in the fair market value of the derivative liabilities of $48,413. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0002 - $0.0008, exercise price of $0.00006 - $0.000483, dividend yield of zero, years to maturity of 0.1616 – 1.66, a risk free rate of 0.02% - 0.67%, and annualized volatility of 152% - 671%. | In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the year ending March 31, 2015: $37,500 note dated March 11, 2014; $53,000 note dated April 8, 2014; $42,500 note dated May 21, 2014; $55,000 note dated September 23, 2014; $66,780 note dated August 14, 2014; $58,300 note dated August 14, 2014; $64,500 note dated September 18, 2014; $58,300 note dated March 2, 2015; $61,111 note dated August 13, 2014; $57,895 note dated August 19, 2014; $33,333 note dated December 16, 2014; $27,778 note dated February 25, 2015. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended March 31, 2015, the Company recorded a total change in the fair market value of the derivative liabilities of $1,867,621. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.001 - $0.037, exercise price of $0.0005 - $0.0203, dividend yield of zero, years to maturity of 0.126 – 1.88, a risk free rate of 0.02% - 0.67%, and annualized volatility of 138% - 403%. The above loans were all discounted in full with the exception of the March 2, 2015 loan which had a debt discount of $46,370. Based on the valuations on the initial valuation dates, the Company recognized debt discounts related to the conversion features totaling $576,370 and a derivative expense of $1,809,914 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of March 31, 2015, unamortized debt discount, including original issue discounts totaling $108,558. The derivative liabilities totaled $217,758 as of March 31, 2015, of which $77,775 related to long-term debt. |
Equity Transactions
Equity Transactions | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Equity Transactions | ||
Equity Transactions | The Company has 37,503,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 82,767,038 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973. On July 19, 2013, our new officer/director agreed to cancel 500,255,434 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares from 90,000,000 to 37,503,000,000. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. On October 29, 2013, the Company granted 250,000 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 11, 2013, the Company granted 250,000 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On March 10, 2014, the Company issued 83,334 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 250,000 250,000 83,334 Stock price on grant date $0.30 $0.02 $0.02 Exercise price $0.50 $0.50 $0.50 Expected life 1 year 1 year 1 year Volatility 147% 64% 65% Risk-free rate 0.12% 0.11% 0.13% Calculated value $10,473 $0 $0 Fair value allocation of proceeds $7,381 $0 $0 On April 4, 2014, the Company issued 83,334 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On April 24, 2014, the Company issued 1,000,000 units at $0.25 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.35 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 10, 2014, the Company issued 700,000 units at $0.043 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.15 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 29, 2014, the Company issued 700,000 units at $0.05 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.15 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On June 9, 2014, the Company issued 90,000,000 units at $0.0002 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.0002 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 June 9, 2015 Warrants 83,334 1,000,000 700,000 700,000 90,000,000 Stock price on grant date $0.199 $0.252 $0.037 $0.037 $0.0002 Exercise price $0.50 $0.35 $0.15 $0.15 $0.0002 Expected life 1 year 3 year 3 year 3 year 5 year Volatility 113% 76% 119% 119% 98% Risk-free rate 0.12% 0.84% 0.96% 0.98% 1.74% Calculated value $3,181 $104,416 $12,130 $12,102 $13,259 Fair value allocation of proceeds $2,822 $73,653 $8,637 $8,992 $13,259 The following is a summary of the warrant activity for the period from April 1, 2013 to June 30, 2015: Number of warrants Weighted average exercise price Outstanding, April 1, 2013 - $0.00 Granted 583,334 $0.50 Exercised - - Outstanding, March 31, 2014 583,334 $0.50 Granted 2,483,334 $0.24 Exercised - - Outstanding, March 31, 2015 3,066,668 $0.29 Granted 90,000,000 $0.0002 Exercised - - Outstanding, June 30, 2015 93,066,668 $0.0097 On May 7, 2014, the Company granted 2,500,000 shares to a consultant for prior services rendered. The Company had accrued $300,000 for these services as of March 31, 2014. On June 16, 2014, the Company issued 1,469,000 shares of common stock for stock deposits of $147,050. The Company had received the deposits during the year ended March 31, 2014. On July 1, 2014, the Company granted 1,000,000 shares to a professional for prior legal services rendered. The Company had accrued $30,000 for these services as of June 30, 2014. The shares were valued on the grant date at the fair market value of $60,000 resulting in a loss on the issuance of shares of $30,000. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC, a related party, and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value of $7,822,235 as a deemed dividend reducing additional paid in capital. Also on October 6, 2014, the Board of Directors approved the issuance of 8,000,000 shares of common stock to the CEO and 4,000,000 shares of common stock to the Company’s attorney as bonuses. The shares were valued based on the closing stock price on the grant date for a total value of $429,600. On November 19, 2105, the Company entered into an agreement with an unrelated vendor to provide six months of consulting services in exchange for 500,000 shares of common stock. The shares were valued based on the closing stock price on the grant date for a total value of $6,450. The entire contract was expensed as of March 31, 2015. On August 13, 2014, the Company entered into an investment agreement with an investor to invest up to $4,000,000 to purchase the Company’s common stock. The price per share for each investment is determined by the lesser of: (1) 65% of the lowest traded price of the Company’s common stock during the ten consecutive trading days prior to the drawdown notice date or (2) 65% of the closing bid price on the day before the drawdown notice is submitted. During the year ended March 31, 2015, the Company issued 79,961,892 shares of common stock to this investor for total proceeds of $220,000. On April 22, 2015, the Company sold 10,038,108 shares of common stock for $5,405 in cash, which was paid directly to a vendor for accounts payable. On June 25, 2015, the Company sold 154,245,477 shares of common stock for $10,797 in cash, of which $3,750 was paid directly to professionals in connection with the expenses of that sale, and $7,047 was retained by the Company. During the year ended March 31, 2015 and the period ended June 30, 2015, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share September 22, 2014 $ 12,000 550,459 $ 0.0218 October 1, 2014 $ 12,000 648,649 $ 0.0185 October 8, 2014 $ 9,000 505,618 $ 0.0178 October 16, 2014 $ 6,000 454,545 $ 0.0132 October 29, 2014 $ 15,000 1,250,000 $ 0.0120 November 3, 2014 $ 10,000 819,672 $ 0.0122 November 7, 2014 $ 12,000 1,188,119 $ 0.0101 November 19, 2014 $ 18,120 2,831,250 $ 0.0064 December 8, 2014 $ 15,000 3,488,372 $ 0.0043 December 15, 2014 $ 12,000 4,285,714 $ 0.0028 December 26, 2014 $ 17,200 7,478,261 $ 0.0023 February 11, 2015 $ 29,900 74,750,000 $ 0.0004 February 12, 2015 $ 17,333 37,356,055 $ 0.00046 February 13, 2015 $ 17,894 37,280,000 $ 0.00048 February 15, 2015 $ 35,730 73,924,324 $ 0.00048 February 17, 2015 $ 17,003 36,643,945 $ 0.00046 February 23, 2015 $ 20,603 47,090,000 $ 0.00044 February 23, 2015 $ 17,003 36,643,945 $ 0.00046 February 24, 2015 $ 9,488 20,447,291 $ 0.00046 February 26, 2015 $ 42,030 105,075,000 $ 0.0004 February 27, 2015 $ 26,880 56,000,000 $ 0.00048 March 2, 2015 $ 56,402 121,555,062 $ 0.00046 March 9, 2015 $ 33,900 47,518,166 $ 0.00071 March 10, 2015 $ 25,200 70,000,000 $ 0.00036 March 20, 2015 $ 10,000 18,181,818 $ 0.00006 March 31, 2015 Total $ 498,686 805,966,265 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $ 16,650 41,111,111 $ 0.00041 April 6, 2015 $ 10,000 20,964,361 $ 0.00048 April 8, 2015 $ 15,309 45,356,111 $ 0.00034 April 8, 2015 $ 20,001 45,454,545 $ 0.00044 April 9, 2015 $ 14,320 32,545,455 $ 0.00044 April 14, 2015 $ 10,000 23,696,682 $ 0.00042 April 16, 2015 $ 1,918 5,300,000 $ 0.00036 April 21, 2015 $ 10,000 25,974,026 $ 0.00039 April 29, 2015 $ 15,000 38,961,039 $ 0.00039 May 4, 2015 $ 5,083 13,146,439 $ 0.00039 May 12, 2015 $ 28,456 90,337,960 $ 0.00031 May 20, 2015 $ 20,199 94,764,514 $ 0.00021 May 20, 015 $ 17,240 78,363,636 $ 0.00022 May 27, 2015 $ 13,568 70,180,137 $ 0.00019 May 29, 2015 $ 15,000 88,235,295 $ 0.00017 June 11, 2015 $ 9,897 94,260,947 $ 0.00010 June 16, 2015 $ 14,100 117,500,000 $ 0.00012 June 16, 2015 $ 13,565 113,041,667 $ 0.00012 June 22, 2015 $ 7,415 123,583,333 $ 0.00006 June 22, 2015 $ 14,384 247,992,413 $ 0.00006 June 23, 2015 $ 7,752 129,200,000 $ 0.00006 June 30, 2015 Total $ 279,857 1,539,969,671 The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined. During the year ended March 31, 2014, the Company granted 47,503,280 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 19,750,000 stock options to officers, directors, employees and consultants. During the period ended June 30, 2015, the Company granted 204,000,250 stock options to officers, directors, employees and consultants The options have been re-priced twice as follows: (1) Effective January 12, 2015, the Company approved the re-pricing of all 67,253,280 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.0191984 per share and $0.30 per share, to $0.0017 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged. (2) Effective April 6, 2015, the Company approved the re-pricing of all 271,253,530 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.0008 per share and $0.0017 per share, to $0.0008 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015 in related stock based compensation expense for those periods. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date September 6, 2013 February 7, 2014 March 14, 2014 May 7, 2014 July 23, 2014 October 6, 2014 Apr il 6, 2015 Options 41,003,280 1,500,000 5,000,000 3,500,000 750,000 15,500,000 204,000,250 Stock price grant date $0.02 $0.02 $0.30 $0.12 $0.069 $.0358 $0.0008 Initial Exercise price $0.0191984 $0.0191984 $0.30 $0.12 $0.069 $0.0191984 $0.0008 Modified Exercise price $0.0008 $0.0008 $0.0008 $0.0008 $0.0008 $0.0008 $0.0008 Expected life 10.00 10.00 10.00 10.00 10.00 5.0 5.0 Volatility 76% 74% 74% 73% 88% 101% 99% Risk-free rate 2.94% 2.71% 2.65% 2.56% 2.53% 1.04% 1.31% Calculated value $663,307 $23,825 $1,182,141 $315,772 $45,109 $454,798 $120,778 Modified value $694,250 $24,920 $1,189,569 $320,159 $45,927 $469,891 $120,778 The following is a summary of the option activity for the period April 1, 2013 through June 30, 2015: Number of options Weighted average exercise price Outstanding, April 1, 2013 - $0.00 Granted 47,503,280 $0.0008 Exercised - - Outstanding, March 31, 2014 47,503,280 $0.0008 Granted 19,750,000 $0.0008 Exercised - - Expired - - Outstanding, March 31, 2015 67,253,280 $0.0008 Granted 204,000,250 $0.0008 Exercised - - Expired - - Outstanding, June 30, 2015 271,253,530 $0.0008 | The Company has 37,503,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 82,767,038 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973. On July 19, 2013, our new officer/director agreed to cancel 500,255,434 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares from 90,000,000 to 37,503,000,000. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. On October 29, 2013, the Company granted 250,000 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 11, 2013, the Company granted 250,000 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On March 10, 2014, the Company issued 83,334 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 250,000 250,000 83,334 Stock price on grant date $ 0.30 $ 0.02 $ 0.02 Exercise price $ 0.50 $ 0.50 $ 0.50 Expected life 1 year 1 year 1 year Volatility 147 % 64 % 65 % Risk-free rate 0.12 % 0.11 % 0.13 % Calculated value $ 10,473 $ 0 $ 0 Fair value allocation of proceeds $ 7,381 $ 0 $ 0 On April 4, 2014, the Company issued 83,334 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On April 24, 2014, the Company issued 1,000,000 units at $0.25 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.35 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 10, 2014, the Company issued 700,000 units at $0.043 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.15 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 29, 2014, the Company issued 700,000 units at $0.05 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.15 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 Warrants 83,334 1,000,000 700,000 700,000 Stock price on grant date $ 0.199 $ 0.252 $ 0.037 $ 0.037 Exercise price $ 0.50 $ 0.35 $ 0.15 $ 0.15 Expected life 1 year 3 year 3 year 3 year Volatility 113 % 76 % 119 % 119 % Risk-free rate 0.12 % 0.84 % 0.96 % 0.98 % Calculated value $ 3,181 $ 104,416 $ 12,130 $ 12,102 Fair value allocation of proceeds $ 2,822 $ 73,653 $ 8,637 $ 8,992 The following is a summary of the warrant activity for the years ended March 31, 2015 and 2014: Number of warrants Weighted average exercise price Outstanding, April 1, 2103 - $0.00 Granted 583,334 $0.50 Exercised - - Outstanding, March 31, 2014 583,334 $0.50 Granted 2,483,334 $0.24 Exercised - - Outstanding, March 31, 2015 3,066,668 $0.29 On May 7, 2014, the Company granted 2,500,000 shares to a consultant for prior services rendered. The Company had accrued $300,000 for these services as of March 31, 2014. On June 16, 2014, the Company issued 1,469,000 shares of common stock for stock deposits of $147,050. The Company had received the deposits during the year ended March 31, 2014. On July 1, 2014, the Company granted 1,000,000 shares to a professional for prior legal services rendered. The Company had accrued $30,000 for these services as of June 30, 2014. The shares were valued on the grant date at the fair market value of $60,000 resulting in a loss on the issuance of shares of $30,000. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC, a related party, and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value of $7,822,235 as a deemed dividend reducing additional paid in capital. Also on October 6, 2014, the Board of Directors approved the issuance of 8,000,000 shares of common stock to the CEO and 4,000,000 shares of common stock to the Company’s attorney as bonuses. The shares were valued based on the closing stock price on the grant date for a total value of $429,600. On November 19, 2015, the Company entered into an agreement with an unrelated vendor to provide six months of consulting services in exchange for 500,000 shares of common stock. The shares were valued based on the closing stock price on the grant date for a total value of $6,450. The entire contract was expensed as of March 31, 2015. On August 13, 2014, the Company entered into an investment agreement with an investor to invest up to $4,000,000 to purchase the Company’s common stock. The price per share for each investment is determined by the lesser of: (1) 65% of the lowest traded price of the Company’s common stock during the ten consecutive trading days prior to the drawdown notice date or (2) 65% of the closing bid price on the day before the drawdown notice is submitted. During the year ended March 31, 2015, the Company issued 79,961,892 shares of common stock to this investor for total proceeds of $220,000. During the year ended March 31, 2015, the Company received twenty-five conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share September 22, 2014 $ 12,000 550,459 $ 0.0218 October 1, 2014 $ 12,000 648,649 $ 0.0185 October 8, 2014 $ 9,000 505,618 $ 0.0178 October 16, 2014 $ 6,000 454,545 $ 0.0132 October 29, 2014 $ 15,000 1,250,000 $ 0.0120 November 3, 2014 $ 10,000 819,672 $ 0.0122 November 7, 2014 $ 12,000 1,188,119 $ 0.0101 November 19, 2014 $ 18,120 2,831,250 $ 0.0064 December 8, 2014 $ 15,000 3,488,372 $ 0.0043 December 15, 2014 $ 12,000 4,285,714 $ 0.0028 December 26, 2014 $ 17,200 7,478,261 $ 0.0023 February 11, 2015 $ 29,900 74,750,000 $ 0.0004 February 12, 2015 $ 17,333 37,356,055 $ 0.00046 February 13, 2015 $ 17,894 37,280,000 $ 0.00048 February 15, 2015 $ 35,730 73,924,324 $ 0.00048 February 17, 2015 $ 17,003 36,643,945 $ 0.00046 February 23, 2015 $ 20,603 47,090,000 $ 0.00044 February 23, 2015 $ 17,003 36,643,945 $ 0.00046 February 24, 2015 $ 9,488 20,447,291 $ 0.00046 February 26, 2015 $ 42,030 105,075,000 $ 0.0004 February 27, 2015 $ 26,880 56,000,000 $ 0.00048 March 2, 2015 $ 56,402 121,555,062 $ 0.00046 March 9, 2015 $ 33,900 47,518,166 $ 0.00071 March 10, 2015 $ 25,200 70,000,000 $ 0.00036 March 20, 2015 $ 10,000 18,181,818 $ 0.00006 Total $ 498,686 805,966,265 The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined. During the year ended March 31, 2014, the Company granted 47,503,280 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 19,750,000 stock options to officers, directors, employees and consultants. Effective January 12, 2015, the Company approved the re-pricing of all 67,253,280 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.0191984 per share and $0.30 per share, to $0.0017 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 in related stock based compensation expense for the year ending March 31, 2015. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date September 6, 2013 February 7, 2014 March 14, 2014 May 7, 2014 July 2 3 , 2014 October 6, 2014 Options 41,003,280 1,500,000 5,000,000 3,500,000 750,000 15,500,000 Stock price grant date $ 0.02 $ 0.02 $ 0.30 $ 0.12 $ 0.069 $ .0358 Initial Exercise price $ 0.0191984 $ 0.0191984 $ 0.30 $ 0.12 $ 0.069 $ 0.0191984 Modified Exercise price $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 Expected life 10.00 10.00 10.00 10.00 10.00 5.0 Volatility 76 % 74 % 74 % 73 % 88 % 101 % Risk-free rate 2.94 % 2.71 % 2.65 % 2.56 % 2.53 % 1.04 % Calculated value $ 663,307 $ 23,825 $ 1,182,141 $ 315,772 $ 45,109 $ 454,798 Modified value $ 689,033 $ 24,737 $ 1,188,971 $ 319,750 $ 45,840 $ 467,069 The following is a summary of the option activity for the years ended March 31, 2015 and 2014: Number of options Weighted average |exercise price Outstanding, April 1, 2013 - $0.00 Granted 47,503,280 $0.0017 Exercised - - Outstanding, March 31, 2014 47,503,280 $0.0017 Granted 19,750,000 $0.0017 Exercised - - Expired - - Outstanding, March 31, 2015 67,253,280 $0.0017 |
Commitments and Contigencies
Commitments and Contigencies | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Accounting Policies [Abstract] | ||
Commitments and Contingencies | The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,600. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. In January 2015, the trial in the Litigation was concluded in the Court. The Court has not rendered a verdict in the Litigation as of the date of filing. The Company believes the allegations in the complaint are without merit and the Company intends to defend itself in the Litigation. However, the Company has incurred expenses and the diversion of financial resources and management personnel in responding to the complaint. Additionally, an adverse determination against the Company in the Litigation may subject us to significant liabilities or require us to seek licenses that may not be available from third parties on commercially favorable terms, if at all. Further, an adverse determination against the Company in the Litigation may require us to pay substantial financial damages, which can be tripled if the infringement is deemed willful, or be required to discontinue or significantly delay development, marketing, selling and licensing of the Company’s affected products and intellectual property rights. | The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,600. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. In January 2015, the trial in the Litigation was concluded in the Court. The Court has not rendered a verdict in the Litigation as of the date of this filing. The Company believes the allegations in the complaint are without merit and the Company intends to defend itself in the Litigation. However, the Company has incurred expenses and the diversion of financial resources and management personnel in responding to the complaint. Additionally, an adverse determination against the Company in the Litigation may subject us to significant liabilities or require us to seek licenses that may not be available from third parties on commercially favorable terms, if at all. Further, an adverse determination against the Company in the Litigation may require us to pay substantial financial damages, which can be tripled if the infringement is deemed willful, or be required to discontinue or significantly delay development, marketing, selling and licensing of the Company’s affected products and intellectual property rights. |
Liquidity and Going Concern
Liquidity and Going Concern | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Liquidity and Going Concern | The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the CompanyÂ’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. ManagementÂ’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts. | The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the CompanyÂ’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. ManagementÂ’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts. |
Income Taxes
Income Taxes | 12 Months Ended |
Mar. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | As of March 31, 2015, the Company had net operating loss carry forwards of approximately $7,220,443 that may be available to reduce future yearsÂ’ taxable income in varying amounts through 2033. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The provision for Federal income tax consists of the following for the years ended March 31, 2015 and 2014: 2015 2014 Federal income tax benefit attributable to: Current operations $ 1,405,416 $ 1,021,679 Less: valuation allowance (1,405,416 ) (1,021,679 ) Net provision for Federal income taxes $ 0 $ 0 The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of March 31, 2015 and 2014: March 31, 2015 March 31, 2014 Deferred tax asset attributable to: Net operating loss carryover $ 2,454,951 $ 1,049,535 Less: valuation allowance (2,454,951 ) (1,049,535 ) Net deferred tax asset $ 0 $ 0 Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $7,220,443 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. |
Subsequent Events
Subsequent Events | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Accounting Policies [Abstract] | ||
Subsequent Events | On July 7, 2015, the Company issued 161,942,326 common stock for $11,335 or $0.00007 per share. On July 15, 2015, the Company issued 143,928,240 common stock for $10,074, or $0.00007 per share. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest rate and is due on April 28, 2016. The loan becomes convertible on August 28, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading price for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the subsequent quarter the Company borrowed $2,000 from a related party. The debt bears no interest and is payable at the convenience of the Company. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to June 30, 2015 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above. | On April 6, 2015, the Company approved an amendment to their 2013 Equity Incentive Plan. This amendment increases the reserved common shares for the plan to 390,004,800. On April 16, 2015, in conjunction with the April 6, 2015 amendment, the board approved the issuance of 204,000,250 new options with an exercise price of $0.0008, grant date of April 16, 2015, and term of 5 years. On April 22, 2015, the Company sold 10,037,107 common shares for $5,405 cash, at a per share price of $0.000498. On June 25, 2015, the Company sold 154,245,477 common shares for $10,797 cash, at a per share price of $0.00007. On July 7, 2015, the Company sold 161,942,326 shares of common stock for $11,336 in cash or $0.00007 per share. On July 15, 2015, the Company sold 143,928,240 shares of common stock for $10,075 in cash, or $0.00007 per share. On June 9, 2015, the Company granted 90,000,000 stock warrants to a legal firm for services rendered. The Company issued the following common shares to satisfy the conversion of the following debt subsequent to the March 31, 2015 year end: Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $ 16,650 41,111,111 $ 0.00041 April 6, 2015 $ 10,000 20,964,361 $ 0.00048 April 8, 2015 $ 15,309 45,356,111 $ 0.00034 April 8, 2015 $ 20,000 45,454,545 $ 0.00044 April 9, 2015 $ 14,320 32,545,455 $ 0.00044 April 14, 2015 $ 10,000 23,696,682 $ 0.00042 April 16, 2015 $ 1,918 5,300,000 $ 0.00036 April 21, 2015 $ 10,000 25,974,026 $ 0.00039 April 29, 2015 $ 15,000 38,961,039 $ 0.00039 May 4, 2015 $ 5,083 13,146,439 $ 0.00039 May 12, 2015 $ 28,456 90,337,960 $ 0.00031 May 20, 2015 $ 20,199 94,764,514 $ 0.00021 May 20, 015 $ 17,240 78,363,636 $ 0.00022 May 27, 2015 $ 13,568 70,180,137 $ 0.00019 May 29, 2015 $ 15,000 88,235,295 $ 0.00017 June 11, 2015 $ 9,897 94,260,947 $ 0.00010 June 16, 2015 $ 14,100 117,500,000 $ 0.00012 June 16, 2015 $ 13,565 113,041,667 $ 0.00012 June 22, 2015 $ 7,415 123,583,333 $ 0.00006 June 22, 2015 $ 14,384 247,992,413 $ 0.00006 June 23, 2015 $ 7,752 129,200,000 $ 0.00006 Total $ 279,857 1,539,969,671 On May 5, 2015, the Company issued a convertible note payable in the amount of $137,800 including an original issue discount of $7,800. This loan contains a front-end funding of $68,900 and a back-end funding of $68,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. On May 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears a one-time 8% interest rate and is due on May 28, 2016. The loan becomes convertible on November 28, 2015, six months from the date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest rate and is due on June 4, 2016. The loan becomes convertible on March 2, 2016, 180 days after the issue date of the note. The loan and any accrued interest can then be converted into shares of the CompanyÂ’s common stock at a rate of 55% multiplied by the market price, which is the average of the two lowest trading price for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. During the subsequent quarter the Company borrowed $13,600 from related parties. The debt bears no interest and is payable at the convenience of the Company. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2015 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above. |
Summary of Significant Accoun21
Summary of Significant Accounting Policies (Policies) | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Accounting Policies [Abstract] | ||
Nature of Business | On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 531,292,500 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 500,255,434 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. | On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 531,292,500 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 500,255,434 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. |
Cash and Cash Equivalents | The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At June 30, 2015 and March 31, 2015 the Company had $90 and $15,892, respectively, of unrestricted cash. | The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2015 and 2014 the Company had $15,892 and $12,387, respectively, of unrestricted cash. |
Basis of Presentation | The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015, as filed with the U.S. Securities and Exchange Commission. | The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. |
Property and Equipment | Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. | Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. |
Long-Lived and Intangible Assets | On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. | On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. |
Fair Value of Financial Instruments | The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at June 30, 2015 and 2014. As of June 30, 2015, the derivative liabilities were considered a level 2 item; see Note 8. | |
Use of Estimates | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. |
Income Taxes | Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. | Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. |
Revenue Recognition | The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. | The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. |
Stock-Based Compensation | Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 390,004,800 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 19,750,000 stock options to officers, directors, employees and consultants. During the period ended June 30, 2015, the Company granted 204,000,250 stock options to officers, directors, employees and consultants. On January 12, 2015, the Company modified the exercise price on all 67,253,280 outstanding stock options to $0.0017. However, on April 6, 2015, the Company again modified the exercise price on all outstanding stock options to $0.0008 per share. | Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. |
Basic loss per share | The basic earnings (loss) per share is calculated by dividing the CompanyÂ’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the CompanyÂ’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. | The basic earnings (loss) per share is calculated by dividing the CompanyÂ’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the CompanyÂ’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. |
Recent Accounting Pronouncements | The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the CompanyÂ’s results of operations, financial position or cash flow. | The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the CompanyÂ’s results of operations, financial position or cash flow. |
Property and equipment (Tables)
Property and equipment (Tables) | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Property, Plant and Equipment [Abstract] | ||
Schedule of Property and Equipment | June 30, 2015 March 31, 2015 Computer equipment $ 1,419 $ 1,419 Less: accumulated depreciation (749 ) (631 ) Property and equipment, net $ 670 $ 788 | 2015 2014 Computer equipment $ 1,419 $ 1,419 Less: accumulated depreciation (631 ) (158 ) Property and equipment, net $ 788 $ 1,261 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Payables and Accruals [Abstract] | ||
Schedule of Accrued Expenses | June 30, 2015 March 31, 2015 Wages and taxes 227,253 175,357 Accrued interest 19,162 25,534 Consulting - - Total accrued expenses $ 246,415 $ 200,891 | 2015 2014 Wages and taxes 175,357 151,290 Accrued interest 25,534 0 Consulting 0 300,000 Total accrued expenses $ 200,891 $ 451,290 |
Equity Transactions (Tables)
Equity Transactions (Tables) | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Accounting Policies [Abstract] | ||
Schedule of Value of Warrants | Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 250,000 250,000 83,334 Stock price on grant date $0.30 $0.02 $0.02 Exercise price $0.50 $0.50 $0.50 Expected life 1 year 1 year 1 year Volatility 147% 64% 65% Risk-free rate 0.12% 0.11% 0.13% Calculated value $10,473 $0 $0 Fair value allocation of proceeds $7,381 $0 $0 Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 June 9, 2015 Warrants 83,334 1,000,000 700,000 700,000 90,000,000 Stock price on grant date $0.199 $0.252 $0.037 $0.037 $0.0002 Exercise price $0.50 $0.35 $0.15 $0.15 $0.0002 Expected life 1 year 3 year 3 year 3 year 5 year Volatility 113% 76% 119% 119% 98% Risk-free rate 0.12% 0.84% 0.96% 0.98% 1.74% Calculated value $3,181 $104,416 $12,130 $12,102 $13,259 Fair value allocation of proceeds $2,822 $73,653 $8,637 $8,992 $13,259 | Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 250,000 250,000 83,334 Stock price on grant date $ 0.30 $ 0.02 $ 0.02 Exercise price $ 0.50 $ 0.50 $ 0.50 Expected life 1 year 1 year 1 year Volatility 147 % 64 % 65 % Risk-free rate 0.12 % 0.11 % 0.13 % Calculated value $ 10,473 $ 0 $ 0 Fair value allocation of proceeds $ 7,381 $ 0 $ 0 Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 Warrants 83,334 1,000,000 700,000 700,000 Stock price on grant date $ 0.199 $ 0.252 $ 0.037 $ 0.037 Exercise price $ 0.50 $ 0.35 $ 0.15 $ 0.15 Expected life 1 year 3 year 3 year 3 year Volatility 113 % 76 % 119 % 119 % Risk-free rate 0.12 % 0.84 % 0.96 % 0.98 % Calculated value $ 3,181 $ 104,416 $ 12,130 $ 12,102 Fair value allocation of proceeds $ 2,822 $ 73,653 $ 8,637 $ 8,992 |
Schedule of Warrant Activity | Number of warrants Weighted average exercise price Outstanding, April 1, 2013 - $0.00 Granted 583,334 $0.50 Exercised - - Outstanding, March 31, 2014 583,334 $0.50 Granted 2,483,334 $0.24 Exercised - - Outstanding, March 31, 2015 3,066,668 $0.29 Granted 90,000,000 $0.0002 Exercised - - Outstanding, June 30, 2015 93,066,668 $0.0097 | Number of warrants Weighted average exercise price Outstanding, April 1, 2103 - $0.00 Granted 583,334 $0.50 Exercised - - Outstanding, March 31, 2014 583,334 $0.50 Granted 2,483,334 $0.24 Exercised - - Outstanding, March 31, 2015 3,066,668 $0.29 |
Schedule of Conversions of Common Stock | Date Debt/Interest Converted Common Stock Issued Price per Share September 22, 2014 $ 12,000 550,459 $ 0.0218 October 1, 2014 $ 12,000 648,649 $ 0.0185 October 8, 2014 $ 9,000 505,618 $ 0.0178 October 16, 2014 $ 6,000 454,545 $ 0.0132 October 29, 2014 $ 15,000 1,250,000 $ 0.0120 November 3, 2014 $ 10,000 819,672 $ 0.0122 November 7, 2014 $ 12,000 1,188,119 $ 0.0101 November 19, 2014 $ 18,120 2,831,250 $ 0.0064 December 8, 2014 $ 15,000 3,488,372 $ 0.0043 December 15, 2014 $ 12,000 4,285,714 $ 0.0028 December 26, 2014 $ 17,200 7,478,261 $ 0.0023 February 11, 2015 $ 29,900 74,750,000 $ 0.0004 February 12, 2015 $ 17,333 37,356,055 $ 0.00046 February 13, 2015 $ 17,894 37,280,000 $ 0.00048 February 15, 2015 $ 35,730 73,924,324 $ 0.00048 February 17, 2015 $ 17,003 36,643,945 $ 0.00046 February 23, 2015 $ 20,603 47,090,000 $ 0.00044 February 23, 2015 $ 17,003 36,643,945 $ 0.00046 February 24, 2015 $ 9,488 20,447,291 $ 0.00046 February 26, 2015 $ 42,030 105,075,000 $ 0.0004 February 27, 2015 $ 26,880 56,000,000 $ 0.00048 March 2, 2015 $ 56,402 121,555,062 $ 0.00046 March 9, 2015 $ 33,900 47,518,166 $ 0.00071 March 10, 2015 $ 25,200 70,000,000 $ 0.00036 March 20, 2015 $ 10,000 18,181,818 $ 0.00006 March 31, 2015 Total $ 498,686 805,966,265 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $ 16,650 41,111,111 $ 0.00041 April 6, 2015 $ 10,000 20,964,361 $ 0.00048 April 8, 2015 $ 15,309 45,356,111 $ 0.00034 April 8, 2015 $ 20,001 45,454,545 $ 0.00044 April 9, 2015 $ 14,320 32,545,455 $ 0.00044 April 14, 2015 $ 10,000 23,696,682 $ 0.00042 April 16, 2015 $ 1,918 5,300,000 $ 0.00036 April 21, 2015 $ 10,000 25,974,026 $ 0.00039 April 29, 2015 $ 15,000 38,961,039 $ 0.00039 May 4, 2015 $ 5,083 13,146,439 $ 0.00039 May 12, 2015 $ 28,456 90,337,960 $ 0.00031 May 20, 2015 $ 20,199 94,764,514 $ 0.00021 May 20, 015 $ 17,240 78,363,636 $ 0.00022 May 27, 2015 $ 13,568 70,180,137 $ 0.00019 May 29, 2015 $ 15,000 88,235,295 $ 0.00017 June 11, 2015 $ 9,897 94,260,947 $ 0.00010 June 16, 2015 $ 14,100 117,500,000 $ 0.00012 June 16, 2015 $ 13,565 113,041,667 $ 0.00012 June 22, 2015 $ 7,415 123,583,333 $ 0.00006 June 22, 2015 $ 14,384 247,992,413 $ 0.00006 June 23, 2015 $ 7,752 129,200,000 $ 0.00006 June 30, 2015 Total $ 279,857 1,539,969,671 | Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 Warrants 83,334 1,000,000 700,000 700,000 Stock price on grant date $ 0.199 $ 0.252 $ 0.037 $ 0.037 Exercise price $ 0.50 $ 0.35 $ 0.15 $ 0.15 Expected life 1 year 3 year 3 year 3 year Volatility 113 % 76 % 119 % 119 % Risk-free rate 0.12 % 0.84 % 0.96 % 0.98 % Calculated value $ 3,181 $ 104,416 $ 12,130 $ 12,102 Fair value allocation of proceeds $ 2,822 $ 73,653 $ 8,637 $ 8,992 |
Schedule of Value of Options | Date September 6, 2013 February 7, 2014 March 14, 2014 May 7, 2014 July 23, 2014 October 6, 2014 Apr il 6, 2015 Options 41,003,280 1,500,000 5,000,000 3,500,000 750,000 15,500,000 204,000,250 Stock price grant date $0.02 $0.02 $0.30 $0.12 $0.069 $.0358 $0.0008 Initial Exercise price $0.0191984 $0.0191984 $0.30 $0.12 $0.069 $0.0191984 $0.0008 Modified Exercise price $0.0008 $0.0008 $0.0008 $0.0008 $0.0008 $0.0008 $0.0008 Expected life 10.00 10.00 10.00 10.00 10.00 5.0 5.0 Volatility 76% 74% 74% 73% 88% 101% 99% Risk-free rate 2.94% 2.71% 2.65% 2.56% 2.53% 1.04% 1.31% Calculated value $663,307 $23,825 $1,182,141 $315,772 $45,109 $454,798 $120,778 Modified value $694,250 $24,920 $1,189,569 $320,159 $45,927 $469,891 $120,778 | Date September 6, 2013 February 7, 2014 March 14, 2014 May 7, 2014 July 2 3 , 2014 October 6, 2014 Options 41,003,280 1,500,000 5,000,000 3,500,000 750,000 15,500,000 Stock price grant date $ 0.02 $ 0.02 $ 0.30 $ 0.12 $ 0.069 $ .0358 Initial Exercise price $ 0.0191984 $ 0.0191984 $ 0.30 $ 0.12 $ 0.069 $ 0.0191984 Modified Exercise price $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 Expected life 10.00 10.00 10.00 10.00 10.00 5.0 Volatility 76 % 74 % 74 % 73 % 88 % 101 % Risk-free rate 2.94 % 2.71 % 2.65 % 2.56 % 2.53 % 1.04 % Calculated value $ 663,307 $ 23,825 $ 1,182,141 $ 315,772 $ 45,109 $ 454,798 Modified value $ 689,033 $ 24,737 $ 1,188,971 $ 319,750 $ 45,840 $ 467,069 |
Schedule of Option Activity | Number of options Weighted average exercise price Outstanding, April 1, 2013 - $0.00 Granted 47,503,280 $0.0008 Exercised - - Outstanding, March 31, 2014 47,503,280 $0.0008 Granted 19,750,000 $0.0008 Exercised - - Expired - - Outstanding, March 31, 2015 67,253,280 $0.0008 Granted 204,000,250 $0.0008 Exercised - - Expired - - Outstanding, June 30, 2015 271,253,530 $0.0008 | Number of options Weighted average |exercise price Outstanding, April 1, 2013 - $0.00 Granted 47,503,280 $0.0017 Exercised - - Outstanding, March 31, 2014 47,503,280 $0.0017 Granted 19,750,000 $0.0017 Exercised - - Expired - - Outstanding, March 31, 2015 67,253,280 $0.0017 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Mar. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Schedule of Federal Income Tax | 2015 2014 Federal income tax benefit attributable to: Current operations $ 1,405,416 $ 1,021,679 Less: valuation allowance (1,405,416 ) (1,021,679 ) Net provision for Federal income taxes $ 0 $ 0 |
Schedule of Deferred Tax Asset | March 31, 2015 March 31, 2014 Deferred tax asset attributable to: Net operating loss carryover $ 2,454,951 $ 1,049,535 Less: valuation allowance (2,454,951 ) (1,049,535 ) Net deferred tax asset $ 0 $ 0 |
Summary of Significant Accoun26
Summary of Significant Accounting Policies (Details Narrative) | 3 Months Ended | 12 Months Ended | |||
Jun. 30, 2015USD ($)$ / sharesshares | Mar. 31, 2015USD ($)$ / sharesshares | Mar. 31, 2014USD ($)$ / sharesshares | Sep. 06, 2013$ / sharesshares | Sep. 05, 2013$ / sharesshares | |
Date Of Incorporation | Aug. 9, 2010 | Aug. 9, 2010 | |||
Common Stock, Shares Authorized | shares | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 | 90,000,000 |
Common Stock, Par Value | $ / shares | $ 0.001 | $ .001 | $ .001 | $ 0.001 | $ 0.001 |
Stock split ratio | 416.7 | ||||
Cash and cash equivalent | $ 90 | $ 15,892 | $ 12,387 | ||
Intangible assets | 0 | ||||
Impairment of intangible asset | $ 82,120 | $ 168,973 | |||
Reserved common shares | shares | 390,004,800 | ||||
Stock options granted | shares | 204,000,250 | ||||
Computer equipment | 3 years | 3 years | |||
Options granted, number of shares | shares | 204,000,250 | 19,750,000 | 47,503,280 | ||
Options, exercise price | $ / shares | $ 0.0008 | $ .0017 | |||
Sale Agmt | |||||
Cancellation of loans | $ 28,818 | $ 28,818 | |||
Shares sold by former officers | shares | 531,292,500 | 531,292,500 | |||
Asset Assign Agmt | |||||
Termination of agreement | $ 20,000 | ||||
Additional cash required | $ 2,000,000 |
Summary of Significant Accoun27
Summary of Significant Accounting Policies 3M (Details Narrative) | 3 Months Ended | 12 Months Ended | |||
Jun. 30, 2015USD ($)$ / sharesshares | Mar. 31, 2015USD ($)$ / sharesshares | Mar. 31, 2014USD ($)$ / sharesshares | Sep. 06, 2013$ / sharesshares | Sep. 05, 2013$ / sharesshares | |
Date Of Incorporation | Aug. 9, 2010 | Aug. 9, 2010 | |||
Common Stock, Shares Authorized | shares | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 | 90,000,000 |
Common Stock, Par Value | $ / shares | $ 0.001 | $ .001 | $ .001 | $ 0.001 | $ 0.001 |
Stock split ratio | 416.7 | ||||
Cash and cash equivalent | $ 90 | $ 15,892 | $ 12,387 | ||
Intangible assets | 0 | ||||
Impairment of intangible asset | $ 82,120 | $ 168,973 | |||
Reserved common shares | shares | 390,004,800 | ||||
Stock options granted | shares | 204,000,250 | ||||
Computer equipment | 3 years | 3 years | |||
Options granted, number of shares | shares | 204,000,250 | 19,750,000 | 47,503,280 | ||
Options, exercise price | $ / shares | $ 0.0008 | $ .0017 | |||
Sale Agmt | |||||
Cancellation of loans | $ 28,818 | $ 28,818 | |||
Shares sold by former officers | shares | 531,292,500 | 531,292,500 | |||
Asset Assign Agmt | |||||
Termination of agreement | $ 20,000 | ||||
Additional cash required | $ 2,000,000 |
Property and equipment - Schedu
Property and equipment - Schedule of Property and Equipment (Details) - USD ($) | Jun. 30, 2015 | Mar. 31, 2015 | Mar. 31, 2014 |
Property, Plant and Equipment [Abstract] | |||
Computer equipment | $ 1,419 | $ 1,419 | $ 1,419 |
Less: accumulated depreciation | (749) | (631) | (158) |
Property and equipment, net | $ 670 | $ 788 | $ 1,261 |
Property and Equipment (Details
Property and Equipment (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |||
Jun. 30, 2015 | Jun. 30, 2014 | Mar. 31, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Property And Equipment Details Narrative | |||||
Depreciation expense | $ 118 | $ 118 | $ 158 | $ 473 | $ 158 |
Computer equipment | 3 years | 3 years |
Intangible Assets (Details Narr
Intangible Assets (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2015 | Mar. 31, 2015 | Mar. 31, 2014 | |
Impairment of intangible asset | $ 82,120 | $ 168,973 | |
Asset Assign Agmt #2 | |||
Date of Agreement | Oct. 6, 2014 | Oct. 6, 2014 | |
Common Stock, shares issued | 220,792,028 | 220,792,028 | |
Common stock, value | $ 7,904,355 | $ 7,904,355 | |
Impaired Assets | 0 | 0 | |
Impairment of intangible asset | $ 82,120 | $ 82,120 | |
Consulting Agreement | |||
Date of Agreement | May 7, 2014 | ||
Common Stock, shares issued | 82,767,038 | 82,767,038 | |
Series A Preferred Stock, shares issued | 6,000,000 | 6,000,000 | |
Common stock, value | $ 123,973 | $ 123,973 | |
Series A Preferred Stock, value | 45,000 | 45,000 | |
Impaired Assets | $ 0 | $ 0 |
Accrued Expenses - Schedule of
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) | Jun. 30, 2015 | Mar. 31, 2015 | Mar. 31, 2014 |
Payables and Accruals [Abstract] | |||
Wages and taxes | $ 227,253 | $ 175,357 | $ 151,290 |
Accrued interest | $ 19,162 | 25,534 | 0 |
Consulting | 0 | 300,000 | |
Total accrued expenses | $ 246,415 | $ 200,891 | $ 451,290 |
Accrued Expenses (Details Narra
Accrued Expenses (Details Narrative) - Consulting Agreement | 12 Months Ended |
Mar. 31, 2014USD ($)shares | |
Agreement date | May 7, 2014 |
Shares issued to consultant | 2,500,000 |
Share issued, value | $ | $ 300,000 |
Related Party Debt and Transa33
Related Party Debt and Transactions (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Jun. 30, 2015 | Jun. 30, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Due to related parties | $ 6,141 | $ 6,067 | $ 36,000 | |
Loans and interest received (repaid) from/to related parties | (31,000) | $ 74 | (29,933) | 40,500 |
Interest expense, related party | (74) | (67) | 0 | |
Sale Agmt | ||||
Cancellation of loans | 28,818 | 28,818 | ||
CEO | ||||
Loan from related party | 5,000 | 5,000 | 36,000 | |
Repayment of loans to related parties | 41,000 | 41,000 | ||
Shareholder | ||||
Loan from related party | 6,000 | $ 6,000 | ||
Interest Rate | 8.00% | |||
Interest expense, related party | $ (67) | $ (67) | ||
Employment Agmt | ||||
Date of Agreement | Sep. 6, 2013 | Sep. 6, 2013 | ||
Term of Agreement | 2 years | 2 years | ||
Annual Compensation | $ 275,000 | $ 275,000 | ||
Options to purchase | 3,000,240 | 3,000,240 | ||
Options to purchase, exercise price | $ 0.02 | $ 0.02 | ||
Bonus | $ 68,750 | $ 68,750 | ||
Earnings | 68,751 | $ 75,711 | 275,000 | 229,167 |
Accrued Earnings | $ 192,113 | $ 154,062 | $ 129,717 |
Related Party Debt and Transa34
Related Party Debt and Transactions 3M (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Jun. 30, 2015 | Jun. 30, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Due to related parties | $ 6,141 | $ 6,067 | $ 36,000 | |
Loans and interest received (repaid) from/to related parties | (31,000) | $ 74 | (29,933) | 40,500 |
Interest expense, related party | (74) | (67) | 0 | |
Sale Agmt | ||||
Cancellation of loans | 28,818 | 28,818 | ||
CEO | ||||
Loan from related party | 5,000 | 5,000 | 36,000 | |
Repayment of loans to related parties | 41,000 | 41,000 | ||
Shareholder | ||||
Loan from related party | 6,000 | $ 6,000 | ||
Interest Rate | 8.00% | |||
Interest expense, related party | $ (67) | $ (67) | ||
Employment Agmt | ||||
Date of Agreement | Sep. 6, 2013 | Sep. 6, 2013 | ||
Term of Agreement | 2 years | 2 years | ||
Annual Compensation | $ 275,000 | $ 275,000 | ||
Options to purchase | 3,000,240 | 3,000,240 | ||
Options to purchase, exercise price | $ 0.02 | $ 0.02 | ||
Bonus | $ 68,750 | $ 68,750 | ||
Earnings | 68,751 | $ 75,711 | 275,000 | 229,167 |
Accrued Earnings | $ 192,113 | $ 154,062 | $ 129,717 |
Stock Deposits (Details Narrati
Stock Deposits (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Notes to Financial Statements | ||
Proceeds from stock deposits | $ 147,050 | $ 147,050 |
Stokc issued in exchange for deposits | 1,469,000 | 1,469,000 |
Convertible Note Payable (Detai
Convertible Note Payable (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Jun. 30, 2015 | Jun. 30, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Debt Instrument, Converted Amount | $ 499,825 | $ 499,825 | $ 499,686 | $ 28,818 |
Convertible Prom Note #1 | ||||
Date of Agreement | Mar. 11, 2014 | Mar. 11, 2014 | ||
Convertible Note | $ 37,500 | $ 37,500 | ||
Interest Rate | 8.00% | 8.00% | ||
Due Date | Dec. 13, 2014 | Dec. 13, 2014 | ||
Interest Accrued | $ 0 | $ 0 | ||
Convertible Note, Balance | 0 | 0 | ||
Debt Instrument, Converted Amount | 37,500 | 37,500 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,500 | $ 1,500 | ||
Common Stock, shares issued | 2,159,271 | 2,159,271 | ||
Convertible Prom Note #2 | ||||
Date of Agreement | Apr. 8, 2014 | Apr. 8, 2014 | ||
Convertible Note | $ 53,000 | $ 53,000 | ||
Interest Rate | 8.00% | 8.00% | ||
Due Date | Jan. 14, 2015 | Jan. 14, 2015 | ||
Interest Accrued | $ 0 | $ 0 | ||
Convertible Note, Balance | 0 | 0 | ||
Debt Instrument, Converted Amount | 53,000 | 53,000 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,120 | $ 2,120 | ||
Common Stock, shares issued | 6,089,041 | 6,089,041 | ||
Convertible Prom Note #3 | ||||
Date of Agreement | May 21, 2014 | May 21, 2014 | ||
Convertible Note | $ 42,500 | $ 42,500 | ||
Interest Rate | 8.00% | 8.00% | ||
Due Date | Feb. 23, 2015 | Feb. 23, 2015 | ||
Interest Accrued | $ 0 | $ 0 | ||
Convertible Note, Balance | 0 | 0 | ||
Debt Instrument, Converted Amount | 42,500 | 42,500 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,700 | $ 1,700 | ||
Common Stock, shares issued | 15,252,347 | 15,252,347 | ||
Convertible Prom Note #4 | ||||
Date of Agreement | Aug. 14, 2014 | Aug. 14, 2014 | ||
Convertible Note | $ 66,780 | $ 66,780 | ||
Interest Rate | 8.00% | 8.00% | ||
Due Date | Aug. 14, 2015 | Aug. 14, 2015 | ||
Interest Accrued | $ 0 | $ 0 | ||
Convertible Note, Balance | 0 | 0 | ||
Original Issue Discount | 3,380 | 3,380 | ||
Debt Instrument, Converted Amount | 66,780 | 66,780 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,850 | $ 2,850 | ||
Common Stock, shares issued | 121,442,490 | 121,442,490 | ||
Convertible Prom Note #5 | ||||
Date of Agreement | Aug. 14, 2014 | Aug. 14, 2014 | ||
Convertible Note | $ 58,300 | $ 58,300 | ||
Interest Rate | 8.00% | 8.00% | ||
Due Date | Aug. 14, 2015 | Aug. 14, 2015 | ||
Interest Accrued | $ 0 | $ 0 | ||
Convertible Note, Balance | 0 | 0 | ||
Original Issue Discount | 3,300 | 3,300 | ||
Debt Instrument, Converted Amount | 58,300 | 58,300 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,527 | $ 2,527 | ||
Common Stock, shares issued | 131,091,236 | 131,091,236 | ||
Convertible Prom Note #6 | ||||
Date of Agreement | Aug. 13, 2014 | |||
Convertible Note | $ 61,111 | |||
Interest Rate | 12.00% | |||
Due Date | Aug. 14, 2016 | |||
Interest Accrued | $ 1,067 | $ 1,067 | ||
Convertible Note, Balance | 0 | |||
Original Issue Discount | 5,500 | |||
Debt Instrument, Converted Amount | 61,111 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 6,266 | |||
Common Stock, shares issued | 140,370,000 | |||
Convertible Prom Note #7 | ||||
Date of Agreement | Aug. 19, 2014 | Aug. 19, 2014 | ||
Convertible Note | $ 57,895 | $ 57,895 | ||
Interest Rate | 12.00% | 12.00% | ||
Due Date | Aug. 19, 2016 | Aug. 19, 2016 | ||
Interest Accrued | $ 0 | $ 0 | ||
Convertible Note, Balance | 0 | 0 | ||
Original Issue Discount | 2,895 | 2,895 | ||
Debt Instrument, Converted Amount | 57,895 | 57,895 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 14,035 | $ 14,035 | ||
Common Stock, shares issued | 179,825,000 | 179,825,000 | ||
Convertible Prom Note #8 | ||||
Date of Agreement | Sep. 18, 2014 | |||
Convertible Note | $ 64,500 | |||
Interest Rate | 12.00% | |||
Due Date | Sep. 18, 2015 | |||
Interest Accrued | $ 7,740 | |||
Convertible Note, Balance | $ 0 | 54,500 | ||
Original Issue Discount | 5,500 | |||
Original Issue Discount, unamortized | 2,523 | |||
Debt Instrument, Converted Amount | 54,500 | $ 10,000 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 8,240 | |||
Common Stock, shares issued | 187,959,744 | 18,181,818 | ||
Convertible Prom Note #9 | ||||
Date of Agreement | Sep. 23, 2014 | |||
Convertible Note | $ 55,000 | |||
Interest Rate | 8.00% | |||
Due Date | Jun. 23, 2015 | |||
Interest Accrued | $ 0 | $ 2,162 | ||
Convertible Note, Balance | 0 | 29,800 | ||
Debt Instrument, Converted Amount | 29,800 | $ 25,200 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,158 | |||
Common Stock, shares issued | 86,467,222 | 70,000,000 | ||
Convertible Prom Note #10 | ||||
Date of Agreement | Oct. 6, 2014 | |||
Convertible Note | $ 33,000 | |||
Interest Rate | 8.00% | |||
Due Date | Jul. 6, 2015 | |||
Interest Accrued | $ 0 | $ 1,273 | ||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | 33,000 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,320 | |||
Common Stock, shares issued | 78,000,000 | |||
Convertible Prom Note #11 | ||||
Date of Agreement | Nov. 6, 2014 | |||
Convertible Note | $ 55,000 | |||
Interest Rate | 12.00% | |||
Due Date | May 6, 2015 | |||
Interest Accrued | $ 0 | $ 2,622 | ||
Convertible Note, Balance | 0 | |||
Debt Instrument, Converted Amount | 55,000 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 3,553 | |||
Common Stock, shares issued | 281,363,421 | |||
Convertible Prom Note #12 | ||||
Date of Agreement | Nov. 25, 2014 | |||
Convertible Note | $ 43,000 | |||
Interest Rate | 8.00% | |||
Due Date | Aug. 28, 2015 | |||
Interest Accrued | $ 1,968 | $ 1,188 | ||
Convertible Note, Balance | 7,020 | |||
Debt Instrument, Converted Amount | $ 35,980 | |||
Common Stock, shares issued | 281,636,421 | |||
Convertible Prom Note #13 | ||||
Date of Agreement | Dec. 16, 2014 | |||
Convertible Note | $ 33,333 | |||
Interest Rate | 12.00% | |||
Due Date | Dec. 16, 2016 | |||
Interest Accrued | $ 4,914 | $ 4,000 | ||
Convertible Note, Balance | 11,481 | |||
Original Issue Discount | 3,333 | |||
Original Issue Discount, unamortized | 2,438 | $ 2,854 | ||
Debt Instrument, Converted Amount | $ 21,852 | |||
Common Stock, shares issued | 246,700,000 | |||
Convertible Prom Note #14 | ||||
Date of Agreement | Jan. 9, 2015 | |||
Convertible Note | $ 33,000 | |||
Interest Rate | 8.00% | |||
Due Date | Oct. 13, 2015 | |||
Interest Accrued | $ 1,244 | $ 586 | ||
Convertible Prom Note #15 | ||||
Date of Agreement | Feb. 5, 2015 | |||
Convertible Note | $ 54,000 | |||
Interest Rate | 8.00% | |||
Due Date | Nov. 9, 2015 | |||
Interest Accrued | 1,716 | $ 639 | ||
Convertible Prom Note #16 | ||||
Date of Agreement | Feb. 17, 2015 | |||
Convertible Note | $ 66,780 | |||
Interest Rate | 8.00% | |||
Due Date | Aug. 14, 2015 | |||
Interest Accrued | 1,006 | $ 615 | ||
Convertible Note, Balance | 34,500 | |||
Original Issue Discount | 6,780 | |||
Original Issue Discount, unamortized | 945 | $ 2,835 | ||
Debt Instrument, Converted Amount | 18,294 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 755 | |||
Common Stock, shares issued | 331,318,989 | |||
Convertible Prom Note #17 | ||||
Date of Agreement | Feb. 25, 2015 | |||
Convertible Note | $ 27,778 | |||
Interest Rate | 12.00% | |||
Due Date | Feb. 25, 2017 | |||
Interest Accrued | $ 4,165 | $ 3,333 | ||
Original Issue Discount, unamortized | 2,302 | $ 2,648 | ||
Convertible Prom Note #18 | ||||
Date of Agreement | Mar. 9, 2015 | |||
Convertible Note | $ 55,000 | |||
Interest Rate | 8.00% | |||
Due Date | Dec. 9, 2015 | |||
Interest Accrued | 1,362 | $ 265 | ||
Convertible Prom Note #19 | ||||
Date of Agreement | Mar. 26, 2015 | |||
Convertible Note | $ 29,680 | |||
Interest Rate | 8.00% | |||
Due Date | Mar. 23, 2016 | |||
Interest Accrued | 624 | $ 32 | ||
Original Issue Discount | 1,680 | |||
Original Issue Discount, unamortized | 1,242 | $ 1,653 | ||
Convertible Prom Note #20 | ||||
Date of Agreement | Mar. 2, 2015 | |||
Convertible Note | $ 58,300 | |||
Interest Rate | 8.00% | |||
Due Date | Aug. 14, 2015 | |||
Interest Accrued | 0 | $ 12 | ||
Convertible Note, Balance | 0 | 1,898 | ||
Original Issue Discount | 3,300 | |||
Original Issue Discount, unamortized | 107 | |||
Debt Instrument, Converted Amount | 1,898 | $ 56,402 | ||
Debt Instrument, Interest Accrued, Converted Amount | $ 20 | |||
Common Stock, shares issued | 5,300,000 | 121,555,062 |
Convertible Note Payable 3M (De
Convertible Note Payable 3M (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |||
Jun. 30, 2015 | Mar. 31, 2015 | Jun. 30, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Debt Instrument, Converted Amount | $ 499,825 | $ 499,825 | $ 499,686 | $ 28,818 | |
Convertible Prom Note #1 | |||||
Date of Agreement | Mar. 11, 2014 | Mar. 11, 2014 | |||
Convertible Note | $ 37,500 | $ 37,500 | |||
Interest Rate | 8.00% | 8.00% | |||
Due Date | Dec. 13, 2014 | Dec. 13, 2014 | |||
Interest Accrued | $ 0 | $ 0 | |||
Convertible Note, Balance | 0 | 0 | |||
Debt Instrument, Converted Amount | 37,500 | 37,500 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,500 | $ 1,500 | |||
Common Stock, shares issued | 2,159,271 | 2,159,271 | |||
Convertible Prom Note #2 | |||||
Date of Agreement | Apr. 8, 2014 | Apr. 8, 2014 | |||
Convertible Note | $ 53,000 | $ 53,000 | |||
Interest Rate | 8.00% | 8.00% | |||
Due Date | Jan. 14, 2015 | Jan. 14, 2015 | |||
Interest Accrued | $ 0 | $ 0 | |||
Convertible Note, Balance | 0 | 0 | |||
Debt Instrument, Converted Amount | 53,000 | 53,000 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,120 | $ 2,120 | |||
Common Stock, shares issued | 6,089,041 | 6,089,041 | |||
Convertible Prom Note #3 | |||||
Date of Agreement | May 21, 2014 | May 21, 2014 | |||
Convertible Note | $ 42,500 | $ 42,500 | |||
Interest Rate | 8.00% | 8.00% | |||
Due Date | Feb. 23, 2015 | Feb. 23, 2015 | |||
Interest Accrued | $ 0 | $ 0 | |||
Convertible Note, Balance | 0 | 0 | |||
Debt Instrument, Converted Amount | 42,500 | 42,500 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,700 | $ 1,700 | |||
Common Stock, shares issued | 15,252,347 | 15,252,347 | |||
Convertible Prom Note #4 | |||||
Date of Agreement | Aug. 14, 2014 | Aug. 14, 2014 | |||
Convertible Note | $ 66,780 | $ 66,780 | |||
Interest Rate | 8.00% | 8.00% | |||
Due Date | Aug. 14, 2015 | Aug. 14, 2015 | |||
Interest Accrued | $ 0 | $ 0 | |||
Convertible Note, Balance | 0 | 0 | |||
Original Issue Discount | 3,380 | 3,380 | |||
Debt Instrument, Converted Amount | 66,780 | 66,780 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,850 | $ 2,850 | |||
Common Stock, shares issued | 121,442,490 | 121,442,490 | |||
Convertible Prom Note #5 | |||||
Date of Agreement | Aug. 14, 2014 | Aug. 14, 2014 | |||
Convertible Note | $ 58,300 | $ 58,300 | |||
Interest Rate | 8.00% | 8.00% | |||
Due Date | Aug. 14, 2015 | Aug. 14, 2015 | |||
Interest Accrued | $ 0 | $ 0 | |||
Convertible Note, Balance | 0 | 0 | |||
Original Issue Discount | 3,300 | 3,300 | |||
Debt Instrument, Converted Amount | 58,300 | 58,300 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,527 | $ 2,527 | |||
Common Stock, shares issued | 131,091,236 | 131,091,236 | |||
Convertible Prom Note #6 | |||||
Date of Agreement | Aug. 13, 2014 | ||||
Convertible Note | $ 61,111 | ||||
Interest Rate | 12.00% | ||||
Due Date | Aug. 14, 2016 | ||||
Interest Accrued | $ 1,067 | $ 1,067 | |||
Convertible Note, Balance | 0 | ||||
Original Issue Discount | 5,500 | ||||
Debt Instrument, Converted Amount | 61,111 | ||||
Debt Instrument, Interest Accrued, Converted Amount | $ 6,266 | ||||
Common Stock, shares issued | 140,370,000 | ||||
Convertible Prom Note #7 | |||||
Date of Agreement | Aug. 19, 2014 | Aug. 19, 2014 | |||
Convertible Note | $ 57,895 | $ 57,895 | |||
Interest Rate | 12.00% | 12.00% | |||
Due Date | Aug. 19, 2016 | Aug. 19, 2016 | |||
Interest Accrued | $ 0 | $ 0 | |||
Convertible Note, Balance | 0 | 0 | |||
Original Issue Discount | 2,895 | 2,895 | |||
Debt Instrument, Converted Amount | 57,895 | 57,895 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 14,035 | $ 14,035 | |||
Common Stock, shares issued | 179,825,000 | 179,825,000 | |||
Convertible Prom Note #8 | |||||
Date of Agreement | Sep. 18, 2014 | ||||
Convertible Note | $ 64,500 | ||||
Interest Rate | 12.00% | ||||
Due Date | Sep. 18, 2015 | ||||
Interest Accrued | $ 7,740 | ||||
Convertible Note, Balance | $ 0 | 54,500 | |||
Original Issue Discount | 5,500 | ||||
Original Issue Discount, unamortized | 2,523 | ||||
Debt Instrument, Converted Amount | 54,500 | $ 10,000 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 8,240 | ||||
Common Stock, shares issued | 187,959,744 | 18,181,818 | |||
Convertible Prom Note #9 | |||||
Date of Agreement | Sep. 23, 2014 | ||||
Convertible Note | $ 55,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jun. 23, 2015 | ||||
Interest Accrued | $ 0 | $ 2,162 | |||
Convertible Note, Balance | 0 | 29,800 | |||
Debt Instrument, Converted Amount | 29,800 | $ 25,200 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 2,158 | ||||
Common Stock, shares issued | 86,467,222 | 70,000,000 | |||
Convertible Prom Note #10 | |||||
Date of Agreement | Oct. 6, 2014 | ||||
Convertible Note | $ 33,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jul. 6, 2015 | ||||
Interest Accrued | $ 0 | $ 1,273 | |||
Convertible Note, Balance | 0 | ||||
Debt Instrument, Converted Amount | 33,000 | ||||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,320 | ||||
Common Stock, shares issued | 78,000,000 | ||||
Convertible Prom Note #11 | |||||
Date of Agreement | Nov. 6, 2014 | ||||
Convertible Note | $ 55,000 | ||||
Interest Rate | 12.00% | ||||
Due Date | May 6, 2015 | ||||
Interest Accrued | $ 0 | $ 2,622 | |||
Convertible Note, Balance | 0 | ||||
Debt Instrument, Converted Amount | 55,000 | ||||
Debt Instrument, Interest Accrued, Converted Amount | $ 3,553 | ||||
Common Stock, shares issued | 281,363,421 | ||||
Convertible Prom Note #12 | |||||
Date of Agreement | Nov. 25, 2014 | ||||
Convertible Note | $ 43,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Aug. 28, 2015 | ||||
Interest Accrued | $ 1,968 | $ 1,188 | |||
Convertible Note, Balance | 7,020 | ||||
Debt Instrument, Converted Amount | $ 35,980 | ||||
Common Stock, shares issued | 281,636,421 | ||||
Convertible Prom Note #13 | |||||
Date of Agreement | Dec. 16, 2014 | ||||
Convertible Note | $ 33,333 | ||||
Interest Rate | 12.00% | ||||
Due Date | Dec. 16, 2016 | ||||
Interest Accrued | $ 4,914 | $ 4,000 | |||
Convertible Note, Balance | 11,481 | ||||
Original Issue Discount | 3,333 | ||||
Original Issue Discount, unamortized | 2,438 | $ 2,854 | |||
Debt Instrument, Converted Amount | $ 21,852 | ||||
Common Stock, shares issued | 246,700,000 | ||||
Convertible Prom Note #14 | |||||
Date of Agreement | Jan. 9, 2015 | ||||
Convertible Note | $ 33,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Oct. 13, 2015 | ||||
Interest Accrued | $ 1,244 | $ 586 | |||
Convertible Prom Note #15 | |||||
Date of Agreement | Feb. 5, 2015 | ||||
Convertible Note | $ 54,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Nov. 9, 2015 | ||||
Interest Accrued | 1,716 | $ 639 | |||
Convertible Prom Note #16 | |||||
Date of Agreement | Feb. 17, 2015 | ||||
Convertible Note | $ 66,780 | ||||
Interest Rate | 8.00% | ||||
Due Date | Aug. 14, 2015 | ||||
Interest Accrued | 1,006 | $ 615 | |||
Convertible Note, Balance | 34,500 | ||||
Original Issue Discount | 6,780 | ||||
Original Issue Discount, unamortized | 945 | $ 2,835 | |||
Debt Instrument, Converted Amount | 18,294 | ||||
Debt Instrument, Interest Accrued, Converted Amount | $ 755 | ||||
Common Stock, shares issued | 331,318,989 | ||||
Convertible Prom Note #17 | |||||
Date of Agreement | Feb. 25, 2015 | ||||
Convertible Note | $ 27,778 | ||||
Interest Rate | 12.00% | ||||
Due Date | Feb. 25, 2017 | ||||
Interest Accrued | $ 4,165 | $ 3,333 | |||
Original Issue Discount, unamortized | 2,302 | $ 2,648 | |||
Convertible Prom Note #18 | |||||
Date of Agreement | Mar. 9, 2015 | ||||
Convertible Note | $ 55,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Dec. 9, 2015 | ||||
Interest Accrued | 1,362 | $ 265 | |||
Convertible Prom Note #19 | |||||
Date of Agreement | Mar. 26, 2015 | ||||
Convertible Note | $ 29,680 | ||||
Interest Rate | 8.00% | ||||
Due Date | Mar. 23, 2016 | ||||
Interest Accrued | 624 | $ 32 | |||
Original Issue Discount | 1,680 | ||||
Original Issue Discount, unamortized | 1,242 | $ 1,653 | |||
Convertible Prom Note #20 | |||||
Date of Agreement | Mar. 2, 2015 | ||||
Convertible Note | $ 58,300 | ||||
Interest Rate | 8.00% | ||||
Due Date | Aug. 14, 2015 | ||||
Interest Accrued | 0 | $ 12 | |||
Convertible Note, Balance | 0 | 1,898 | |||
Original Issue Discount | 3,300 | ||||
Original Issue Discount, unamortized | 107 | ||||
Debt Instrument, Converted Amount | 1,898 | $ 56,402 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 20 | ||||
Common Stock, shares issued | 5,300,000 | 121,555,062 | |||
Convertible Prom Note #21 | |||||
Date of Agreement | May 5, 2015 | ||||
Convertible Note | $ 68,900 | ||||
Interest Rate | 8.00% | ||||
Due Date | May 5, 2016 | ||||
Interest Accrued | $ 846 | ||||
Original Issue Discount | 3,250 | ||||
Convertible Prom Note #22 | |||||
Date of Agreement | May 6, 2015 | ||||
Convertible Note | $ 10,500 | ||||
Interest Rate | 8.00% | ||||
Due Date | Feb. 8, 2016 | ||||
Interest Accrued | 127 | ||||
Convertible Prom Note #23 | |||||
Date of Agreement | May 27, 2015 | ||||
Convertible Note | $ 16,500 | ||||
Interest Rate | 8.00% | ||||
Due Date | May 28, 2016 | ||||
Interest Accrued | 123 | ||||
Original Issue Discount, unamortized | $ 1,354 |
Derivative Liabilities (Details
Derivative Liabilities (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Jun. 30, 2015 | Jun. 30, 2014 | Mar. 31, 2015 | Mar. 31, 2014 | |
Notes to Financial Statements | ||||
Change in value of derivative liability | $ (48,413) | $ (1,867,621) | $ 0 | |
Derivative expense | 191,844 | (1,809,914) | 0 | |
Debt Discount, Unamortized | 165,629 | |||
Derivative liabilities | $ 109,035 | $ 77,775 | $ 0 |
Equity Transactions - Schedule
Equity Transactions - Schedule of Value of Warrants (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Warrant #1 | ||
Date | Oct. 29, 2013 | Oct. 29, 2013 |
Warrants | $ 250,000 | $ 250,000 |
Stock price on grant date | $ 0.30 | $ 0.30 |
Exercise price | $ 0.50 | $ 0.50 |
Expected life | 1 year | 1 year |
Volatility | 147.00% | 147.00% |
Risk-free rate | 0.12% | 0.12% |
Calculated value | $ 10,473 | $ 10,473 |
Fair value allocation of proceeds | $ 7,381 | $ 7,381 |
Warrant #2 | ||
Date | Dec. 11, 2013 | Dec. 11, 2013 |
Warrants | $ 250,000 | $ 250,000 |
Stock price on grant date | $ 0.30 | $ 0.30 |
Exercise price | $ 0.50 | $ 0.50 |
Expected life | 1 year | 1 year |
Volatility | 64.00% | 64.00% |
Risk-free rate | 0.11% | 0.11% |
Calculated value | $ 0 | $ 0 |
Fair value allocation of proceeds | $ 0 | $ 0 |
Warrant #3 | ||
Date | Mar. 10, 2014 | Mar. 10, 2014 |
Warrants | $ 83,334 | $ 83,334 |
Stock price on grant date | $ 0.30 | $ 0.30 |
Exercise price | $ 0.50 | $ 0.50 |
Expected life | 1 year | 1 year |
Volatility | 65.00% | 65.00% |
Risk-free rate | 0.13% | 0.13% |
Calculated value | $ 0 | $ 0 |
Fair value allocation of proceeds | $ 0 | $ 0 |
Warrant #4 | ||
Date | Apr. 4, 2014 | Apr. 4, 2014 |
Warrants | $ 83,334 | $ 83,334 |
Stock price on grant date | $ 0.30 | $ 0.30 |
Exercise price | $ 0.50 | $ 0.50 |
Expected life | 1 year | 1 year |
Volatility | 113.00% | 113.00% |
Risk-free rate | 0.12% | 0.12% |
Calculated value | $ 3,181 | $ 3,181 |
Fair value allocation of proceeds | $ 2,822 | $ 3,181 |
Warrant #5 | ||
Date | Apr. 24, 2014 | Apr. 15, 2014 |
Warrants | $ 1,000,000 | $ 1,000,000 |
Stock price on grant date | $ 0.25 | $ 0.25 |
Exercise price | $ 0.35 | $ 0.35 |
Expected life | 3 years | 3 years |
Volatility | 76.00% | 76.00% |
Risk-free rate | 0.84% | 0.84% |
Calculated value | $ 104,416 | $ 104,416 |
Fair value allocation of proceeds | $ 73,653 | $ 104,416 |
Warrant #6 | ||
Date | Jul. 10, 2014 | Jul. 10, 2014 |
Warrants | $ 700,000 | $ 700,000 |
Stock price on grant date | $ 0.037 | $ 0.037 |
Exercise price | $ 0.15 | $ 0.15 |
Expected life | 3 years | 3 years |
Volatility | 119.00% | 119.00% |
Risk-free rate | 0.96% | 0.96% |
Calculated value | $ 12,130 | $ 12,130 |
Fair value allocation of proceeds | $ 8,627 | $ 8,637 |
Warrant #7 | ||
Date | Jul. 29, 2014 | Jul. 29, 2014 |
Warrants | $ 700,000 | $ 700,000 |
Stock price on grant date | $ 0.037 | $ 0.037 |
Exercise price | $ 0.15 | $ 0.15 |
Expected life | 3 years | 3 years |
Volatility | 119.00% | 119.00% |
Risk-free rate | 0.98% | 0.98% |
Calculated value | $ 12,102 | $ 12,102 |
Fair value allocation of proceeds | $ 8,992 | $ 8,992 |
Warrant #8 | ||
Date | Jun. 9, 2015 | |
Warrants | $ 90,000,000 | |
Stock price on grant date | $ 0.0002 | |
Exercise price | $ 0.0002 | |
Expected life | 5 years | |
Volatility | 98.00% | |
Risk-free rate | 1.74% | |
Calculated value | $ 13,259 | |
Fair value allocation of proceeds | $ 13,259 |
Equity Transactions - Schedul40
Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2015 | Mar. 31, 2015 | Mar. 31, 2014 | |
Accounting Policies [Abstract] | |||
Beginning Balance, Issued Warrants | 3,066,668 | 583,334 | 583,334 |
Beginning Balance, Average Exercise Price | $ 0.29 | $ 0.50 | $ .50 |
Issued, Warrants | 90,000,000 | 2,483,334 | |
Issued, Average Exercise Price | $ 0.0002 | $ 0.24 | |
Exercised, Warrants | |||
Exercised, Average Exercise Price | |||
Expired Warrants | |||
Expired Average Exercise Price | |||
Ending Balance, Issued Warrants | 93,066,668 | 3,066,668 | 583,334 |
Ending Balance, Average Exercise Price | $ 0.0097 | $ 0.29 | $ 0.50 |
Equity Transactions - Schedul41
Equity Transactions - Schedule of Value of Options (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Jun. 30, 2015 | Mar. 31, 2015 | |
Stock Option 1 | ||
Date of Issuance | Sep. 6, 2013 | Sep. 6, 2013 |
Options | 41,003,280 | 41,003,280 |
Stock price on grant date | $ 0.02 | $ 0.02 |
Exercise price | $ 0.0191984 | $ 0.0191984 |
Expected life | 10 years | 10 years |
Volatility | 76.00% | 76.00% |
Risk-free rate | 2.94% | 2.94% |
Calculated value | $ 663,307 | $ 663,307 |
Stock Option 2 | ||
Date of Issuance | Feb. 7, 2014 | Feb. 7, 2014 |
Options | 1,500,000 | 1,500,000 |
Stock price on grant date | $ 0.02 | $ 0.02 |
Exercise price | $ 0.0191984 | $ 0.0191984 |
Expected life | 10 years | 10 years |
Volatility | 74.00% | 74.00% |
Risk-free rate | 2.71% | 2.71% |
Calculated value | $ 23,825 | $ 23,825 |
Stock Option 3 | ||
Date of Issuance | Mar. 14, 2014 | Mar. 14, 2014 |
Options | 5,000,000 | 5,000,000 |
Stock price on grant date | $ 0.30 | $ 0.30 |
Exercise price | $ 0.30 | $ 0.30 |
Expected life | 10 years | 10 years |
Volatility | 74.00% | 74.00% |
Risk-free rate | 2.65% | 2.65% |
Calculated value | $ 1,182,141 | $ 1,182,141 |
Stock Option 4 | ||
Date of Issuance | May 7, 2014 | May 7, 2014 |
Options | 3,500,000 | 3,500,000 |
Stock price on grant date | $ 0.12 | $ .12 |
Exercise price | $ 0.12 | $ .12 |
Expected life | 10 years | 10 years |
Volatility | 73.00% | 73.00% |
Risk-free rate | 2.56% | 2.56% |
Calculated value | $ 315,772 | $ 315,772 |
Stock Option 5 | ||
Date of Issuance | Jul. 23, 2014 | Jul. 23, 2014 |
Options | 750,000 | 750,000 |
Stock price on grant date | $ 0.069 | $ .069 |
Exercise price | $ 0.069 | $ .069 |
Expected life | 10 years | 10 years |
Volatility | 88.00% | 88.00% |
Risk-free rate | 2.53% | 2.53% |
Calculated value | $ 45,109 | $ 45,109 |
Stock Option 6 | ||
Date of Issuance | Oct. 6, 2014 | Oct. 6, 2014 |
Options | 15,500,000 | 15,500,000 |
Stock price on grant date | $ 0.0358 | $ .0358 |
Exercise price | $ 0.0191984 | $ .0191984 |
Expected life | 5 years | 5 years |
Volatility | 101.00% | 101.00% |
Risk-free rate | 1.04% | 1.04% |
Calculated value | $ 454,798 | $ 454,798 |
Stock Option 7 | ||
Date of Issuance | Apr. 6, 2015 | |
Options | 204,000,250 | |
Stock price on grant date | $ 0.0008 | |
Exercise price | $ 0.0008 | |
Expected life | 5 years | |
Volatility | 99.00% | |
Risk-free rate | 1.31% | |
Calculated value | $ 120,788 |
Equity Transactions - Schedul42
Equity Transactions - Schedule of Option Activity (Details) - shares | 3 Months Ended | 12 Months Ended | |
Jun. 30, 2015 | Mar. 31, 2015 | Mar. 31, 2014 | |
Accounting Policies [Abstract] | |||
Beginning Balance, number of shares | 67,253,280 | 47,503,280 | 47,503,280 |
Beginning Balance, weighted average exercise price | 0.0008 | 0.0017 | 0.0017 |
Options granted, number of shares | 204,000,250 | 19,750,000 | 47,503,280 |
Options granted, weighted average exercise price | 0.0008 | .0017 | |
Options exercised, number of shares | |||
Options exercised, weighted average exercise price | |||
Options expired, number of shares | |||
Options expired, weighted average exercise price | |||
Ending Balance, number of shares | 271,253,530 | 67,253,280 | 47,503,280 |
Ending Balance, weighted average exercise price | 0.0008 | 0.0008 | 0.0017 |
Equity Transactions (Details Na
Equity Transactions (Details Narrative) | 3 Months Ended | 12 Months Ended | |||||
Jun. 30, 2015USD ($)$ / sharesshares | Jun. 30, 2014USD ($) | Mar. 31, 2015USD ($)$ / sharesshares | Mar. 31, 2014USD ($)$ / sharesshares | Sep. 06, 2013$ / sharesshares | Sep. 05, 2013$ / sharesshares | Jul. 18, 2013shares | |
Common Stock, Shares Authorized | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 | 90,000,000 | ||
Common Stock, Par Value | $ / shares | $ 0.001 | $ .001 | $ .001 | $ 0.001 | $ 0.001 | ||
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 | 10,000,000 | ||||
Preferred Stock, Par Value | $ / shares | $ 0.001 | $ .001 | $ .001 | ||||
Series A Preferred Stock, Designated | 6,000,000 | ||||||
Common Stock, Issued | 3,245,337,213 | 1,541,083,957 | 414,411,438 | ||||
Preferred Stock, Issued | 6,000,000 | 6,000,000 | 6,000,000 | ||||
Stock split ratio | 416.7 | ||||||
Options granted, number of shares | 204,000,250 | 19,750,000 | 47,503,280 | ||||
Shares issued for services, value | $ | $ 796,050 | $ 796,050 | $ 0 | ||||
Debt Instrument, Converted Amount | $ | $ 499,825 | $ 499,825 | $ 499,686 | $ 28,818 | |||
Warrant #6 | |||||||
Common Stock, shares issued | 700,000 | 700,000 | |||||
Date | Jul. 10, 2014 | Jul. 10, 2014 | |||||
Warrants | $ | $ 700,000 | $ 700,000 | |||||
Stock price on grant date | $ / shares | $ 0.043 | $ 0.043 | |||||
Exercise price | $ / shares | $ 0.15 | $ 0.15 | |||||
Expected life | 3 years | 3 years | |||||
Warrant #7 | |||||||
Common Stock, shares issued | 700,000 | 700,000 | |||||
Date | Jul. 29, 2014 | Jul. 29, 2014 | |||||
Warrants | $ | $ 700,000 | $ 700,000 | |||||
Stock price on grant date | $ / shares | $ 0.05 | $ 0.05 | |||||
Exercise price | $ / shares | $ 0.15 | $ 0.15 | |||||
Expected life | 3 years | 3 years | |||||
Debt Conversion #1 | |||||||
Date of Agreement | Sep. 22, 2014 | Sep. 22, 2014 | |||||
Common Stock, shares issued | 550,459 | 550,459 | |||||
Common Stock, price per share | $ / shares | $ 0.0218 | $ 0.0218 | |||||
Debt Instrument, Converted Amount | $ | $ 12,000 | $ 12,000 | |||||
Debt Conversion #2 | |||||||
Date of Agreement | Oct. 1, 2014 | Oct. 1, 2014 | |||||
Common Stock, shares issued | 648,649 | 648,649 | |||||
Common Stock, price per share | $ / shares | $ 0.0185 | $ 0.0185 | |||||
Debt Instrument, Converted Amount | $ | $ 12,000 | $ 12,000 | |||||
Debt Conversion #3 | |||||||
Date of Agreement | Oct. 8, 2014 | Oct. 8, 2014 | |||||
Common Stock, shares issued | 505,618 | 505,618 | |||||
Common Stock, price per share | $ / shares | $ 0.0178 | $ 0.0178 | |||||
Debt Instrument, Converted Amount | $ | $ 9,000 | $ 9,000 | |||||
Debt Conversion #4 | |||||||
Date of Agreement | Oct. 16, 2014 | Oct. 16, 2014 | |||||
Common Stock, shares issued | 454,545 | 454,545 | |||||
Common Stock, price per share | $ / shares | $ 0.0132 | $ 0.0132 | |||||
Debt Instrument, Converted Amount | $ | $ 6,000 | $ 6,000 | |||||
Debt Conversion #5 | |||||||
Date of Agreement | Oct. 29, 2014 | Oct. 29, 2014 | |||||
Common Stock, shares issued | 1,250,000 | 1,250,000 | |||||
Common Stock, price per share | $ / shares | $ 0.0120 | $ 0.0120 | |||||
Debt Instrument, Converted Amount | $ | $ 15,000 | $ 15,000 | |||||
Debt Conversion #6 | |||||||
Date of Agreement | Nov. 3, 2014 | Nov. 3, 2014 | |||||
Common Stock, shares issued | 819,672 | 819,672 | |||||
Common Stock, price per share | $ / shares | $ 0.0122 | $ 0.0122 | |||||
Debt Instrument, Converted Amount | $ | $ 10,000 | $ 10,000 | |||||
Debt Conversion #7 | |||||||
Date of Agreement | Nov. 7, 2014 | Nov. 7, 2014 | |||||
Common Stock, shares issued | 1,188,119 | 1,188,119 | |||||
Common Stock, price per share | $ / shares | $ 0.0101 | $ 0.0101 | |||||
Debt Instrument, Converted Amount | $ | $ 12,000 | $ 12,000 | |||||
Debt Conversion #8 | |||||||
Date of Agreement | Nov. 19, 2014 | Nov. 19, 2014 | |||||
Common Stock, shares issued | 2,831,250 | 2,831,250 | |||||
Common Stock, price per share | $ / shares | $ 0.0064 | $ 0.0064 | |||||
Debt Instrument, Converted Amount | $ | $ 18,120 | $ 18,120 | |||||
Debt Conversion #9 | |||||||
Date of Agreement | Dec. 8, 2014 | Dec. 8, 2014 | |||||
Common Stock, shares issued | 3,488,372 | 3,488,372 | |||||
Common Stock, price per share | $ / shares | $ 0.0043 | $ 0.0043 | |||||
Debt Instrument, Converted Amount | $ | $ 15,000 | $ 15,000 | |||||
Debt Conversion #10 | |||||||
Date of Agreement | Dec. 15, 2014 | Dec. 15, 2014 | |||||
Common Stock, shares issued | 4,285,714 | 4,285,714 | |||||
Common Stock, price per share | $ / shares | $ 0.0028 | $ 0.0028 | |||||
Debt Instrument, Converted Amount | $ | $ 12,000 | $ 12,000 | |||||
Debt Conversion #11 | |||||||
Date of Agreement | Dec. 26, 2014 | Dec. 26, 2014 | |||||
Common Stock, shares issued | 7,478,261 | 7,478,261 | |||||
Common Stock, price per share | $ / shares | $ 0.0023 | $ 0.0023 | |||||
Debt Instrument, Converted Amount | $ | $ 17,200 | $ 17,200 | |||||
Debt Conversion #12 | |||||||
Date of Agreement | Feb. 11, 2015 | Feb. 11, 2015 | |||||
Common Stock, shares issued | 74,750,000 | 74,750,000 | |||||
Common Stock, price per share | $ / shares | $ 0.0004 | $ 0.0004 | |||||
Debt Instrument, Converted Amount | $ | $ 29,900 | $ 29,900 | |||||
Debt Conversion #13 | |||||||
Date of Agreement | Feb. 12, 2015 | Feb. 12, 2015 | |||||
Common Stock, shares issued | 37,356,055 | 37,356,055 | |||||
Common Stock, price per share | $ / shares | $ 0.00046 | $ 0.00046 | |||||
Debt Instrument, Converted Amount | $ | $ 17,333 | $ 17,333 | |||||
Debt Conversion #14 | |||||||
Date of Agreement | Feb. 15, 2015 | Feb. 15, 2015 | |||||
Common Stock, shares issued | 73,924,324 | 73,924,324 | |||||
Common Stock, price per share | $ / shares | $ 0.00048 | $ 0.00048 | |||||
Debt Instrument, Converted Amount | $ | $ 35,730 | $ 35,730 | |||||
Legal Services | |||||||
Shares issued for services | 1,000,000 | ||||||
Shares issued for services, value | $ | $ 30,000 | ||||||
Date | Jul. 1, 2014 | ||||||
Asset Assign Agmt #2 | |||||||
Date of Agreement | Oct. 6, 2014 | Oct. 6, 2014 | |||||
Common Stock, shares issued | 220,792,028 | 220,792,028 | |||||
Shares Issued, Value | $ | $ 7,904,355 | $ 7,904,355 | |||||
Asset Assign Agmt | |||||||
Date of Agreement | Jul. 18, 2015 | Jul. 18, 2015 | |||||
Common Stock, shares issued | 82,767,038 | 82,767,038 | |||||
Series A Preferred Stock, shares issued | 6,000,000 | 6,000,000 | |||||
Shares Issued, Value | $ | $ 123,973 | $ 123,973 | |||||
Sale Agmt | |||||||
Shares agreed to cancel | 262,521,000 | 262,521,000 | |||||
Shares returned to treasury | 500,255,434 | 500,255,434 | |||||
Date of Agreement | Jul. 19, 2013 | Jul. 19, 2013 | |||||
Consultant | |||||||
Shares issued for services | 2,500,000 | 2,500,000 | |||||
Shares issued for services, value | $ | $ 300,000 | $ 300,000 | |||||
Date | May 7, 2014 | May 7, 2014 | |||||
Stock Deposits | |||||||
Common Stock, shares issued | 1,469,000 | 1,469,000 | |||||
Shares Issued, Value | $ | $ 147,050 | $ 147,050 | |||||
Date | Jun. 16, 2014 | Jun. 16, 2014 | |||||
Warrant #1 | |||||||
Common Stock, shares issued | 250,000 | 250,000 | |||||
Date | Oct. 29, 2013 | Oct. 29, 2013 | |||||
Warrants | $ | $ 250,000 | $ 250,000 | |||||
Stock price on grant date | $ / shares | $ 0.30 | $ 0.30 | |||||
Exercise price | $ / shares | $ 0.50 | $ 0.50 | |||||
Expected life | 1 year | 1 year | |||||
Warrant #2 | |||||||
Common Stock, shares issued | 250,000 | 250,000 | |||||
Date | Dec. 11, 2013 | Dec. 11, 2013 | |||||
Warrants | $ | $ 250,000 | $ 250,000 | |||||
Stock price on grant date | $ / shares | $ 0.30 | $ 0.30 | |||||
Exercise price | $ / shares | $ 0.50 | $ 0.50 | |||||
Expected life | 1 year | 1 year | |||||
Warrant #3 | |||||||
Common Stock, shares issued | 83,334 | 83,334 | |||||
Date | Mar. 10, 2014 | Mar. 10, 2014 | |||||
Warrants | $ | $ 83,334 | $ 83,334 | |||||
Stock price on grant date | $ / shares | $ 0.30 | $ 0.30 | |||||
Exercise price | $ / shares | $ 0.50 | $ 0.50 | |||||
Expected life | 1 year | 1 year | |||||
Warrant #4 | |||||||
Common Stock, shares issued | 83,334 | 83,334 | |||||
Date | Apr. 4, 2014 | Apr. 4, 2014 | |||||
Warrants | $ | $ 83,334 | $ 83,334 | |||||
Stock price on grant date | $ / shares | $ 0.30 | $ 0.30 | |||||
Exercise price | $ / shares | $ 0.50 | $ 0.50 | |||||
Expected life | 1 year | 1 year | |||||
Warrant #5 | |||||||
Common Stock, shares issued | 1,000,000 | 1,000,000 | |||||
Date | Apr. 24, 2014 | Apr. 15, 2014 | |||||
Warrants | $ | $ 1,000,000 | $ 1,000,000 | |||||
Stock price on grant date | $ / shares | $ 0.25 | $ 0.25 | |||||
Exercise price | $ / shares | $ 0.35 | $ 0.35 | |||||
Expected life | 3 years | 3 years | |||||
CEO | |||||||
Date of Agreement | Oct. 6, 2014 | Oct. 6, 2014 | |||||
Shares issued for services | 8,000,000 | 8,000,000 | |||||
Attorney | |||||||
Date of Agreement | Oct. 6, 2014 | Oct. 6, 2014 | |||||
Shares issued for services | 4,000,000 | 4,000,000 | |||||
Vendor | |||||||
Shares issued for services | 500,000 | 500,000 | |||||
Shares issued for services, value | $ | $ 6,450 | $ 6,450 | |||||
Investment Agmt | |||||||
Date of Agreement | Aug. 13, 2014 | Aug. 13, 2014 | |||||
Shares issued for services | 79,961,892 | 79,961,892 | |||||
Shares issued for services, value | $ | $ 220,000 | $ 220,000 | |||||
Debt Conversion #15 | |||||||
Date of Agreement | Feb. 13, 2015 | Feb. 13, 2015 | |||||
Common Stock, shares issued | 37,280,000 | 37,280,000 | |||||
Common Stock, price per share | $ / shares | $ 0.00048 | $ 0.00048 | |||||
Debt Instrument, Converted Amount | $ | $ 17,894 | $ 17,894 | |||||
Debt Conversion #16 | |||||||
Date of Agreement | Feb. 17, 2015 | Feb. 17, 2015 | |||||
Common Stock, shares issued | 36,643,945 | 36,643,945 | |||||
Common Stock, price per share | $ / shares | $ 0.00046 | $ 0.00046 | |||||
Debt Instrument, Converted Amount | $ | $ 17,003 | $ 17,003 | |||||
Debt Conversion #17 | |||||||
Date of Agreement | Feb. 23, 2015 | Feb. 23, 2015 | |||||
Common Stock, shares issued | 47,090,000 | 47,090,000 | |||||
Common Stock, price per share | $ / shares | $ 0.00044 | $ 0.00044 | |||||
Debt Instrument, Converted Amount | $ | $ 20,603 | $ 20,603 | |||||
Debt Conversion #18 | |||||||
Date of Agreement | Feb. 23, 2015 | Feb. 23, 2015 | |||||
Common Stock, shares issued | 36,643,945 | 36,643,945 | |||||
Common Stock, price per share | $ / shares | $ 0.00046 | $ 0.00046 | |||||
Debt Instrument, Converted Amount | $ | $ 17,003 | $ 17,003 | |||||
Debt Conversion #19 | |||||||
Date of Agreement | Feb. 24, 2015 | Feb. 24, 2015 | |||||
Common Stock, shares issued | 20,447,291 | 20,447,291 | |||||
Common Stock, price per share | $ / shares | $ 0.00046 | $ 0.00046 | |||||
Debt Instrument, Converted Amount | $ | $ 9,488 | $ 9,488 | |||||
Debt Conversion #20 | |||||||
Date of Agreement | Feb. 26, 2015 | Feb. 26, 2015 | |||||
Common Stock, shares issued | 105,075,000 | 105,075,000 | |||||
Common Stock, price per share | $ / shares | $ 0.0004 | $ 0.0004 | |||||
Debt Instrument, Converted Amount | $ | $ 42,030 | $ 42,030 | |||||
Debt Conversion #21 | |||||||
Date of Agreement | Feb. 27, 2015 | Feb. 27, 2015 | |||||
Common Stock, shares issued | 56,000,000 | 56,000,000 | |||||
Common Stock, price per share | $ / shares | $ 0.00048 | $ 0.00048 | |||||
Debt Instrument, Converted Amount | $ | $ 26,880 | $ 26,880 | |||||
Debt Conversion #22 | |||||||
Date of Agreement | Mar. 2, 2015 | Mar. 2, 2015 | |||||
Common Stock, shares issued | 121,555,062 | 121,555,062 | |||||
Common Stock, price per share | $ / shares | $ 0.00046 | $ 0.00046 | |||||
Debt Instrument, Converted Amount | $ | $ 56,402 | $ 56,402 | |||||
Debt Conversion #23 | |||||||
Date of Agreement | Mar. 9, 2015 | Mar. 9, 2015 | |||||
Common Stock, shares issued | 47,518,166 | 47,518,166 | |||||
Common Stock, price per share | $ / shares | $ 0.00071 | $ 0.00071 | |||||
Debt Instrument, Converted Amount | $ | $ 33,900 | $ 33,900 | |||||
Debt Conversion #24 | |||||||
Date of Agreement | Mar. 10, 2015 | Mar. 10, 2015 | |||||
Common Stock, shares issued | 70,000,000 | 70,000,000 | |||||
Common Stock, price per share | $ / shares | $ 0.00036 | $ 0.00036 | |||||
Debt Instrument, Converted Amount | $ | $ 25,200 | $ 25,200 | |||||
Debt Conversion #25 | |||||||
Date of Agreement | Mar. 20, 2015 | Mar. 20, 2015 | |||||
Common Stock, shares issued | 18,181,818 | 18,181,818 | |||||
Common Stock, price per share | $ / shares | $ 0.00006 | $ 0.00006 | |||||
Debt Instrument, Converted Amount | $ | $ 10,000 | $ 10,000 |
Equity Transactions 3M (Details
Equity Transactions 3M (Details Narrative) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||
Jun. 30, 2015USD ($)$ / sharesshares | Mar. 31, 2015USD ($)$ / sharesshares | Jun. 30, 2014USD ($) | Jun. 30, 2015USD ($)$ / sharesshares | Mar. 31, 2015USD ($)$ / sharesshares | Mar. 31, 2014USD ($)$ / sharesshares | Sep. 06, 2013$ / sharesshares | Sep. 05, 2013$ / sharesshares | Jul. 18, 2013shares | |
Common Stock, Shares Authorized | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 | 37,503,000,000 | 90,000,000 | ||
Common Stock, Par Value | $ / shares | $ 0.001 | $ .001 | $ 0.001 | $ .001 | $ .001 | $ 0.001 | $ 0.001 | ||
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | ||||
Preferred Stock, Par Value | $ / shares | $ 0.001 | $ .001 | $ 0.001 | $ .001 | $ .001 | ||||
Series A Preferred Stock, Designated | 6,000,000 | ||||||||
Common Stock, Issued | 3,245,337,213 | 1,541,083,957 | 3,245,337,213 | 1,541,083,957 | 414,411,438 | ||||
Preferred Stock, Issued | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | ||||
Stock split ratio | 416.7 | ||||||||
Options granted, number of shares | 204,000,250 | 19,750,000 | 47,503,280 | ||||||
Shares issued for services, value | $ | $ 796,050 | $ 796,050 | $ 0 | ||||||
Debt Instrument, Converted Amount | $ | $ 499,825 | $ 499,825 | $ 499,686 | $ 28,818 | |||||
Legal Services | |||||||||
Shares issued for services | 1,000,000 | ||||||||
Shares issued for services, value | $ | $ 30,000 | ||||||||
Date | Jul. 1, 2014 | ||||||||
Warrant #6 | |||||||||
Common Stock, shares issued | 700,000 | 700,000 | |||||||
Date | Jul. 10, 2014 | Jul. 10, 2014 | |||||||
Warrants | $ | $ 700,000 | $ 700,000 | |||||||
Stock price on grant date | $ / shares | $ 0.043 | $ 0.043 | |||||||
Exercise price | $ / shares | $ 0.15 | $ 0.15 | |||||||
Expected life | 3 years | 3 years | |||||||
Warrant #7 | |||||||||
Common Stock, shares issued | 700,000 | 700,000 | |||||||
Date | Jul. 29, 2014 | Jul. 29, 2014 | |||||||
Warrants | $ | $ 700,000 | $ 700,000 | |||||||
Stock price on grant date | $ / shares | $ 0.05 | $ 0.05 | |||||||
Exercise price | $ / shares | $ 0.15 | $ 0.15 | |||||||
Expected life | 3 years | 3 years | |||||||
Debt Conversion #1 | |||||||||
Date of Agreement | Sep. 22, 2014 | Sep. 22, 2014 | |||||||
Common Stock, shares issued | 550,459 | 550,459 | |||||||
Common Stock, price per share | $ / shares | $ 0.0218 | $ 0.0218 | |||||||
Debt Instrument, Converted Amount | $ | $ 12,000 | $ 12,000 | |||||||
Debt Conversion #2 | |||||||||
Date of Agreement | Oct. 1, 2014 | Oct. 1, 2014 | |||||||
Common Stock, shares issued | 648,649 | 648,649 | |||||||
Common Stock, price per share | $ / shares | $ 0.0185 | $ 0.0185 | |||||||
Debt Instrument, Converted Amount | $ | $ 12,000 | $ 12,000 | |||||||
Debt Conversion #3 | |||||||||
Date of Agreement | Oct. 8, 2014 | Oct. 8, 2014 | |||||||
Common Stock, shares issued | 505,618 | 505,618 | |||||||
Common Stock, price per share | $ / shares | $ 0.0178 | $ 0.0178 | |||||||
Debt Instrument, Converted Amount | $ | $ 9,000 | $ 9,000 | |||||||
Debt Conversion #4 | |||||||||
Date of Agreement | Oct. 16, 2014 | Oct. 16, 2014 | |||||||
Common Stock, shares issued | 454,545 | 454,545 | |||||||
Common Stock, price per share | $ / shares | $ 0.0132 | $ 0.0132 | |||||||
Debt Instrument, Converted Amount | $ | $ 6,000 | $ 6,000 | |||||||
Debt Conversion #5 | |||||||||
Date of Agreement | Oct. 29, 2014 | Oct. 29, 2014 | |||||||
Common Stock, shares issued | 1,250,000 | 1,250,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.0120 | $ 0.0120 | |||||||
Debt Instrument, Converted Amount | $ | $ 15,000 | $ 15,000 | |||||||
Debt Conversion #6 | |||||||||
Date of Agreement | Nov. 3, 2014 | Nov. 3, 2014 | |||||||
Common Stock, shares issued | 819,672 | 819,672 | |||||||
Common Stock, price per share | $ / shares | $ 0.0122 | $ 0.0122 | |||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | $ 10,000 | |||||||
Debt Conversion #7 | |||||||||
Date of Agreement | Nov. 7, 2014 | Nov. 7, 2014 | |||||||
Common Stock, shares issued | 1,188,119 | 1,188,119 | |||||||
Common Stock, price per share | $ / shares | $ 0.0101 | $ 0.0101 | |||||||
Debt Instrument, Converted Amount | $ | $ 12,000 | $ 12,000 | |||||||
Debt Conversion #8 | |||||||||
Date of Agreement | Nov. 19, 2014 | Nov. 19, 2014 | |||||||
Common Stock, shares issued | 2,831,250 | 2,831,250 | |||||||
Common Stock, price per share | $ / shares | $ 0.0064 | $ 0.0064 | |||||||
Debt Instrument, Converted Amount | $ | $ 18,120 | $ 18,120 | |||||||
Debt Conversion #9 | |||||||||
Date of Agreement | Dec. 8, 2014 | Dec. 8, 2014 | |||||||
Common Stock, shares issued | 3,488,372 | 3,488,372 | |||||||
Common Stock, price per share | $ / shares | $ 0.0043 | $ 0.0043 | |||||||
Debt Instrument, Converted Amount | $ | $ 15,000 | $ 15,000 | |||||||
Debt Conversion #10 | |||||||||
Date of Agreement | Dec. 15, 2014 | Dec. 15, 2014 | |||||||
Common Stock, shares issued | 4,285,714 | 4,285,714 | |||||||
Common Stock, price per share | $ / shares | $ 0.0028 | $ 0.0028 | |||||||
Debt Instrument, Converted Amount | $ | $ 12,000 | $ 12,000 | |||||||
Debt Conversion #11 | |||||||||
Date of Agreement | Dec. 26, 2014 | Dec. 26, 2014 | |||||||
Common Stock, shares issued | 7,478,261 | 7,478,261 | |||||||
Common Stock, price per share | $ / shares | $ 0.0023 | $ 0.0023 | |||||||
Debt Instrument, Converted Amount | $ | $ 17,200 | $ 17,200 | |||||||
Debt Conversion #12 | |||||||||
Date of Agreement | Feb. 11, 2015 | Feb. 11, 2015 | |||||||
Common Stock, shares issued | 74,750,000 | 74,750,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.0004 | $ 0.0004 | |||||||
Debt Instrument, Converted Amount | $ | $ 29,900 | $ 29,900 | |||||||
Debt Conversion #13 | |||||||||
Date of Agreement | Feb. 12, 2015 | Feb. 12, 2015 | |||||||
Common Stock, shares issued | 37,356,055 | 37,356,055 | |||||||
Common Stock, price per share | $ / shares | $ 0.00046 | $ 0.00046 | |||||||
Debt Instrument, Converted Amount | $ | $ 17,333 | $ 17,333 | |||||||
Debt Conversion #14 | |||||||||
Date of Agreement | Feb. 15, 2015 | Feb. 15, 2015 | |||||||
Common Stock, shares issued | 73,924,324 | 73,924,324 | |||||||
Common Stock, price per share | $ / shares | $ 0.00048 | $ 0.00048 | |||||||
Debt Instrument, Converted Amount | $ | $ 35,730 | $ 35,730 | |||||||
Debt Conversion #26 | |||||||||
Date of Agreement | Apr. 1, 2015 | ||||||||
Common Stock, shares issued | 41,111,111 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00041 | ||||||||
Debt Instrument, Converted Amount | $ | $ 16,650 | ||||||||
Debt Conversion #27 | |||||||||
Date of Agreement | Apr. 6, 2015 | ||||||||
Common Stock, shares issued | 20,964,361 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00048 | ||||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | ||||||||
Debt Conversion #28 | |||||||||
Date of Agreement | Apr. 8, 2015 | ||||||||
Common Stock, shares issued | 45,356,111 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00034 | ||||||||
Debt Instrument, Converted Amount | $ | $ 15,309 | ||||||||
Debt Conversion #29 | |||||||||
Date of Agreement | Apr. 9, 2015 | ||||||||
Common Stock, shares issued | 32,545,455 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00044 | ||||||||
Debt Instrument, Converted Amount | $ | $ 14,320 | ||||||||
Debt Conversion #30 | |||||||||
Date of Agreement | Apr. 14, 2015 | ||||||||
Common Stock, shares issued | 23,696,682 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00042 | ||||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | ||||||||
Debt Conversion #31 | |||||||||
Date of Agreement | Apr. 16, 2015 | ||||||||
Common Stock, shares issued | 5,300,000 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00036 | ||||||||
Debt Instrument, Converted Amount | $ | $ 1,918 | ||||||||
Debt Conversion #32 | |||||||||
Date of Agreement | Apr. 21, 2015 | ||||||||
Common Stock, shares issued | 25,974,026 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00036 | ||||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | ||||||||
Debt Conversion #33 | |||||||||
Date of Agreement | Apr. 29, 2015 | ||||||||
Common Stock, shares issued | 38,961,039 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00039 | ||||||||
Debt Instrument, Converted Amount | $ | $ 15,000 | ||||||||
Debt Conversion #34 | |||||||||
Date of Agreement | May 4, 2015 | ||||||||
Common Stock, shares issued | 13,146,439 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00039 | ||||||||
Debt Instrument, Converted Amount | $ | $ 5,083 | ||||||||
Debt Conversion #35 | |||||||||
Date of Agreement | May 12, 2015 | ||||||||
Common Stock, shares issued | 90,337,960 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00031 | ||||||||
Debt Instrument, Converted Amount | $ | $ 28,456 | ||||||||
Debt Conversion #36 | |||||||||
Date of Agreement | May 20, 2015 | ||||||||
Common Stock, shares issued | 94,764,514 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00021 | ||||||||
Debt Instrument, Converted Amount | $ | $ 20,199 | ||||||||
Debt Conversion #37 | |||||||||
Date of Agreement | May 20, 2015 | ||||||||
Common Stock, shares issued | 78,363,636 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00022 | ||||||||
Debt Instrument, Converted Amount | $ | $ 17,240 | ||||||||
Debt Conversion #38 | |||||||||
Date of Agreement | May 27, 2015 | ||||||||
Common Stock, shares issued | 70,180,137 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00019 | ||||||||
Debt Instrument, Converted Amount | $ | $ 13,568 | ||||||||
Debt Conversion #39 | |||||||||
Date of Agreement | May 29, 2015 | ||||||||
Common Stock, shares issued | 88,235,295 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00017 | ||||||||
Debt Instrument, Converted Amount | $ | $ 15,000 | ||||||||
Debt Conversion #40 | |||||||||
Date of Agreement | Jun. 11, 2015 | ||||||||
Common Stock, shares issued | 94,260,947 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00010 | ||||||||
Debt Instrument, Converted Amount | $ | $ 9,897 | ||||||||
Debt Conversion #41 | |||||||||
Date of Agreement | Jun. 16, 2015 | ||||||||
Common Stock, shares issued | 117,500,000 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00012 | ||||||||
Debt Instrument, Converted Amount | $ | $ 14,100 | ||||||||
Debt Conversion #42 | |||||||||
Date of Agreement | Jun. 16, 2015 | ||||||||
Common Stock, shares issued | 113,041,667 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00012 | ||||||||
Debt Instrument, Converted Amount | $ | $ 13,565 | ||||||||
Debt Conversion #43 | |||||||||
Date of Agreement | Apr. 8, 2015 | Apr. 8, 2015 | |||||||
Common Stock, shares issued | 45,454,545 | 45,454,545 | |||||||
Common Stock, price per share | $ / shares | $ 0.00044 | $ 0.00044 | |||||||
Debt Instrument, Converted Amount | $ | $ 20,000 | $ 20,000 | |||||||
Debt Conversion #44 | |||||||||
Date of Agreement | Jun. 22, 2015 | Jun. 22, 2015 | |||||||
Common Stock, shares issued | 123,583,333 | 123,583,333 | |||||||
Common Stock, price per share | $ / shares | $ 0.00006 | $ 0.00006 | |||||||
Debt Instrument, Converted Amount | $ | $ 7,415 | $ 7,415 | |||||||
Debt Conversion #45 | |||||||||
Date of Agreement | Jun. 22, 2015 | Jun. 22, 2015 | |||||||
Common Stock, shares issued | 247,992,413 | 247,992,413 | |||||||
Common Stock, price per share | $ / shares | $ 0.00006 | $ 0.00006 | |||||||
Debt Instrument, Converted Amount | $ | $ 14,384 | $ 14,384 | |||||||
Debt Conversion #46 | |||||||||
Date of Agreement | Jun. 23, 2015 | Jun. 23, 2015 | |||||||
Common Stock, shares issued | 129,200,000 | 129,200,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00006 | $ 0.00006 | |||||||
Debt Instrument, Converted Amount | $ | $ 7,752 | $ 7,752 | |||||||
Grant of Stock | |||||||||
Common Stock, shares issued | 90,000,000 | ||||||||
Date | Jun. 9, 2014 | ||||||||
Warrants | $ | $ 90,000,000 | ||||||||
Stock price on grant date | $ / shares | $ 0.0002 | ||||||||
Exercise price | $ / shares | $ 0.0002 | ||||||||
Expected life | 5 years | ||||||||
Sale of Stock #1 | |||||||||
Common Stock, shares issued | 10,037,107 | ||||||||
Common Stock, price per share | $ / shares | $ 0.000498 | ||||||||
Sale of Stock #2 | |||||||||
Common Stock, shares issued | 154,245,477 | ||||||||
Common Stock, price per share | $ / shares | $ 0.00007 | ||||||||
2013 Stock Option Plan Amendment | |||||||||
Exercise price | $ / shares | $ 0.0008 | ||||||||
Asset Assign Agmt #2 | |||||||||
Date of Agreement | Oct. 6, 2014 | Oct. 6, 2014 | |||||||
Common Stock, shares issued | 220,792,028 | 220,792,028 | |||||||
Shares Issued, Value | $ | $ 7,904,355 | $ 7,904,355 | |||||||
Asset Assign Agmt | |||||||||
Date of Agreement | Jul. 18, 2015 | Jul. 18, 2015 | |||||||
Common Stock, shares issued | 82,767,038 | 82,767,038 | |||||||
Series A Preferred Stock, shares issued | 6,000,000 | 6,000,000 | |||||||
Shares Issued, Value | $ | $ 123,973 | $ 123,973 | |||||||
Sale Agmt | |||||||||
Shares agreed to cancel | 262,521,000 | 262,521,000 | |||||||
Shares returned to treasury | 500,255,434 | 500,255,434 | |||||||
Date of Agreement | Jul. 19, 2013 | Jul. 19, 2013 | |||||||
Consultant | |||||||||
Shares issued for services | 2,500,000 | 2,500,000 | |||||||
Shares issued for services, value | $ | $ 300,000 | $ 300,000 | |||||||
Date | May 7, 2014 | May 7, 2014 | |||||||
Stock Deposits | |||||||||
Common Stock, shares issued | 1,469,000 | 1,469,000 | |||||||
Shares Issued, Value | $ | $ 147,050 | $ 147,050 | |||||||
Date | Jun. 16, 2014 | Jun. 16, 2014 | |||||||
Warrant #1 | |||||||||
Common Stock, shares issued | 250,000 | 250,000 | |||||||
Date | Oct. 29, 2013 | Oct. 29, 2013 | |||||||
Warrants | $ | $ 250,000 | $ 250,000 | |||||||
Stock price on grant date | $ / shares | $ 0.30 | $ 0.30 | |||||||
Exercise price | $ / shares | $ 0.50 | $ 0.50 | |||||||
Expected life | 1 year | 1 year | |||||||
Warrant #2 | |||||||||
Common Stock, shares issued | 250,000 | 250,000 | |||||||
Date | Dec. 11, 2013 | Dec. 11, 2013 | |||||||
Warrants | $ | $ 250,000 | $ 250,000 | |||||||
Stock price on grant date | $ / shares | $ 0.30 | $ 0.30 | |||||||
Exercise price | $ / shares | $ 0.50 | $ 0.50 | |||||||
Expected life | 1 year | 1 year | |||||||
Warrant #3 | |||||||||
Common Stock, shares issued | 83,334 | 83,334 | |||||||
Date | Mar. 10, 2014 | Mar. 10, 2014 | |||||||
Warrants | $ | $ 83,334 | $ 83,334 | |||||||
Stock price on grant date | $ / shares | $ 0.30 | $ 0.30 | |||||||
Exercise price | $ / shares | $ 0.50 | $ 0.50 | |||||||
Expected life | 1 year | 1 year | |||||||
Warrant #4 | |||||||||
Common Stock, shares issued | 83,334 | 83,334 | |||||||
Date | Apr. 4, 2014 | Apr. 4, 2014 | |||||||
Warrants | $ | $ 83,334 | $ 83,334 | |||||||
Stock price on grant date | $ / shares | $ 0.30 | $ 0.30 | |||||||
Exercise price | $ / shares | $ 0.50 | $ 0.50 | |||||||
Expected life | 1 year | 1 year | |||||||
Warrant #5 | |||||||||
Common Stock, shares issued | 1,000,000 | 1,000,000 | |||||||
Date | Apr. 24, 2014 | Apr. 15, 2014 | |||||||
Warrants | $ | $ 1,000,000 | $ 1,000,000 | |||||||
Stock price on grant date | $ / shares | $ 0.25 | $ 0.25 | |||||||
Exercise price | $ / shares | $ 0.35 | $ 0.35 | |||||||
Expected life | 3 years | 3 years | |||||||
CEO | |||||||||
Date of Agreement | Oct. 6, 2014 | Oct. 6, 2014 | |||||||
Shares issued for services | 8,000,000 | 8,000,000 | |||||||
Attorney | |||||||||
Date of Agreement | Oct. 6, 2014 | Oct. 6, 2014 | |||||||
Shares issued for services | 4,000,000 | 4,000,000 | |||||||
Vendor | |||||||||
Shares issued for services | 500,000 | 500,000 | |||||||
Shares issued for services, value | $ | $ 6,450 | $ 6,450 | |||||||
Investment Agmt | |||||||||
Date of Agreement | Aug. 13, 2014 | Aug. 13, 2014 | |||||||
Shares issued for services | 79,961,892 | 79,961,892 | |||||||
Shares issued for services, value | $ | $ 220,000 | $ 220,000 | |||||||
Debt Conversion #15 | |||||||||
Date of Agreement | Feb. 13, 2015 | Feb. 13, 2015 | |||||||
Common Stock, shares issued | 37,280,000 | 37,280,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00048 | $ 0.00048 | |||||||
Debt Instrument, Converted Amount | $ | $ 17,894 | $ 17,894 | |||||||
Debt Conversion #16 | |||||||||
Date of Agreement | Feb. 17, 2015 | Feb. 17, 2015 | |||||||
Common Stock, shares issued | 36,643,945 | 36,643,945 | |||||||
Common Stock, price per share | $ / shares | $ 0.00046 | $ 0.00046 | |||||||
Debt Instrument, Converted Amount | $ | $ 17,003 | $ 17,003 | |||||||
Debt Conversion #17 | |||||||||
Date of Agreement | Feb. 23, 2015 | Feb. 23, 2015 | |||||||
Common Stock, shares issued | 47,090,000 | 47,090,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00044 | $ 0.00044 | |||||||
Debt Instrument, Converted Amount | $ | $ 20,603 | $ 20,603 | |||||||
Debt Conversion #18 | |||||||||
Date of Agreement | Feb. 23, 2015 | Feb. 23, 2015 | |||||||
Common Stock, shares issued | 36,643,945 | 36,643,945 | |||||||
Common Stock, price per share | $ / shares | $ 0.00046 | $ 0.00046 | |||||||
Debt Instrument, Converted Amount | $ | $ 17,003 | $ 17,003 | |||||||
Debt Conversion #19 | |||||||||
Date of Agreement | Feb. 24, 2015 | Feb. 24, 2015 | |||||||
Common Stock, shares issued | 20,447,291 | 20,447,291 | |||||||
Common Stock, price per share | $ / shares | $ 0.00046 | $ 0.00046 | |||||||
Debt Instrument, Converted Amount | $ | $ 9,488 | $ 9,488 | |||||||
Debt Conversion #20 | |||||||||
Date of Agreement | Feb. 26, 2015 | Feb. 26, 2015 | |||||||
Common Stock, shares issued | 105,075,000 | 105,075,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.0004 | $ 0.0004 | |||||||
Debt Instrument, Converted Amount | $ | $ 42,030 | $ 42,030 | |||||||
Debt Conversion #21 | |||||||||
Date of Agreement | Feb. 27, 2015 | Feb. 27, 2015 | |||||||
Common Stock, shares issued | 56,000,000 | 56,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00048 | $ 0.00048 | |||||||
Debt Instrument, Converted Amount | $ | $ 26,880 | $ 26,880 | |||||||
Debt Conversion #22 | |||||||||
Date of Agreement | Mar. 2, 2015 | Mar. 2, 2015 | |||||||
Common Stock, shares issued | 121,555,062 | 121,555,062 | |||||||
Common Stock, price per share | $ / shares | $ 0.00046 | $ 0.00046 | |||||||
Debt Instrument, Converted Amount | $ | $ 56,402 | $ 56,402 | |||||||
Debt Conversion #23 | |||||||||
Date of Agreement | Mar. 9, 2015 | Mar. 9, 2015 | |||||||
Common Stock, shares issued | 47,518,166 | 47,518,166 | |||||||
Common Stock, price per share | $ / shares | $ 0.00071 | $ 0.00071 | |||||||
Debt Instrument, Converted Amount | $ | $ 33,900 | $ 33,900 | |||||||
Debt Conversion #24 | |||||||||
Date of Agreement | Mar. 10, 2015 | Mar. 10, 2015 | |||||||
Common Stock, shares issued | 70,000,000 | 70,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00036 | $ 0.00036 | |||||||
Debt Instrument, Converted Amount | $ | $ 25,200 | $ 25,200 | |||||||
Debt Conversion #25 | |||||||||
Date of Agreement | Mar. 20, 2015 | Mar. 20, 2015 | |||||||
Common Stock, shares issued | 18,181,818 | 18,181,818 | |||||||
Common Stock, price per share | $ / shares | $ 0.00006 | $ 0.00006 | |||||||
Debt Instrument, Converted Amount | $ | $ 10,000 | $ 10,000 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) | Mar. 31, 2015USD ($) |
Accounting Policies [Abstract] | |
Monthly Rent | $ 2,600 |
Income Taxes - Schedule of Fede
Income Taxes - Schedule of Federal Income Tax (Details) - USD ($) | 12 Months Ended | |
Mar. 31, 2015 | Mar. 31, 2014 | |
Federal income tax benefit attributable to: | ||
Current operations | $ 1,405,416 | $ 1,021,679 |
Less: valuation allowance | (1,405,416) | (1,021,679) |
Net provision for Federal income taxes | $ 0 | $ 0 |
Income Taxes - Schedule of Defe
Income Taxes - Schedule of Deferred Tax Asset (Details) - USD ($) | Mar. 31, 2015 | Mar. 31, 2014 |
Deferred tax asset attributable to: | ||
Net operating loss carryover | $ 2,454,951 | $ 1,049,535 |
Less: valuation allowance | (2,454,951) | (1,049,535) |
Net deferred tax asset | $ 0 | $ 0 |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) | 12 Months Ended |
Mar. 31, 2015USD ($) | |
Income Tax Disclosure [Abstract] | |
Net Operating Loss Carry-Forwards | $ 7,220,443 |
Operating Loss Carry-Forwards Expiration Date | Jan. 1, 2033 |
Effective Tax Rate | 34.00% |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2015 | Mar. 31, 2015 | Jun. 30, 2014 | Jun. 30, 2015 | Dec. 31, 2015 | Mar. 31, 2015 | Mar. 31, 2014 | |
Issued, Warrants | 90,000,000 | 2,483,334 | |||||
Common Stock, value | $ 220,000 | ||||||
Debt Instrument, Converted Amount | $ 499,825 | $ 499,825 | $ 499,686 | $ 28,818 | |||
Reserved common shares | 390,004,800 | 390,004,800 | |||||
Due to related parties | $ 6,141 | $ 6,067 | $ 6,141 | $ 6,067 | $ 36,000 | ||
Debt Conversion #26 | |||||||
Common Stock, shares issued | 41,111,111 | ||||||
Common Stock, price per share | $ 0.00041 | ||||||
Date of Agreement | Apr. 1, 2015 | ||||||
Debt Instrument, Converted Amount | $ 16,650 | ||||||
Debt Conversion #27 | |||||||
Common Stock, shares issued | 20,964,361 | ||||||
Common Stock, price per share | $ 0.00048 | ||||||
Date of Agreement | Apr. 6, 2015 | ||||||
Debt Instrument, Converted Amount | $ 10,000 | ||||||
Debt Conversion #28 | |||||||
Common Stock, shares issued | 45,356,111 | ||||||
Common Stock, price per share | $ 0.00034 | ||||||
Date of Agreement | Apr. 8, 2015 | ||||||
Debt Instrument, Converted Amount | $ 15,309 | ||||||
Debt Conversion #43 | |||||||
Common Stock, shares issued | 45,454,545 | 45,454,545 | |||||
Common Stock, price per share | $ 0.00044 | $ 0.00044 | |||||
Date of Agreement | Apr. 8, 2015 | Apr. 8, 2015 | |||||
Debt Instrument, Converted Amount | $ 20,000 | $ 20,000 | |||||
Debt Conversion #29 | |||||||
Common Stock, shares issued | 32,545,455 | ||||||
Common Stock, price per share | $ 0.00044 | ||||||
Date of Agreement | Apr. 9, 2015 | ||||||
Debt Instrument, Converted Amount | $ 14,320 | ||||||
Debt Conversion #30 | |||||||
Common Stock, shares issued | 23,696,682 | ||||||
Common Stock, price per share | $ 0.00042 | ||||||
Date of Agreement | Apr. 14, 2015 | ||||||
Debt Instrument, Converted Amount | $ 10,000 | ||||||
Debt Conversion #31 | |||||||
Common Stock, shares issued | 5,300,000 | ||||||
Common Stock, price per share | $ 0.00036 | ||||||
Date of Agreement | Apr. 16, 2015 | ||||||
Debt Instrument, Converted Amount | $ 1,918 | ||||||
Debt Conversion #32 | |||||||
Common Stock, shares issued | 25,974,026 | ||||||
Common Stock, price per share | $ 0.00036 | ||||||
Date of Agreement | Apr. 21, 2015 | ||||||
Debt Instrument, Converted Amount | $ 10,000 | ||||||
Debt Conversion #33 | |||||||
Common Stock, shares issued | 38,961,039 | ||||||
Common Stock, price per share | $ 0.00039 | ||||||
Date of Agreement | Apr. 29, 2015 | ||||||
Debt Instrument, Converted Amount | $ 15,000 | ||||||
Debt Conversion #34 | |||||||
Common Stock, shares issued | 13,146,439 | ||||||
Common Stock, price per share | $ 0.00039 | ||||||
Date of Agreement | May 4, 2015 | ||||||
Debt Instrument, Converted Amount | $ 5,083 | ||||||
Debt Conversion #35 | |||||||
Common Stock, shares issued | 90,337,960 | ||||||
Common Stock, price per share | $ 0.00031 | ||||||
Date of Agreement | May 12, 2015 | ||||||
Debt Instrument, Converted Amount | $ 28,456 | ||||||
Debt Conversion #36 | |||||||
Common Stock, shares issued | 94,764,514 | ||||||
Common Stock, price per share | $ 0.00021 | ||||||
Date of Agreement | May 20, 2015 | ||||||
Debt Instrument, Converted Amount | $ 20,199 | ||||||
Debt Conversion #37 | |||||||
Common Stock, shares issued | 78,363,636 | ||||||
Common Stock, price per share | $ 0.00022 | ||||||
Date of Agreement | May 20, 2015 | ||||||
Debt Instrument, Converted Amount | $ 17,240 | ||||||
Debt Conversion #38 | |||||||
Common Stock, shares issued | 70,180,137 | ||||||
Common Stock, price per share | $ 0.00019 | ||||||
Date of Agreement | May 27, 2015 | ||||||
Debt Instrument, Converted Amount | $ 13,568 | ||||||
Debt Conversion #39 | |||||||
Common Stock, shares issued | 88,235,295 | ||||||
Common Stock, price per share | $ 0.00017 | ||||||
Date of Agreement | May 29, 2015 | ||||||
Debt Instrument, Converted Amount | $ 15,000 | ||||||
Debt Conversion #40 | |||||||
Common Stock, shares issued | 94,260,947 | ||||||
Common Stock, price per share | $ 0.00010 | ||||||
Date of Agreement | Jun. 11, 2015 | ||||||
Debt Instrument, Converted Amount | $ 9,897 | ||||||
Debt Conversion #41 | |||||||
Common Stock, shares issued | 117,500,000 | ||||||
Common Stock, price per share | $ 0.00012 | ||||||
Date of Agreement | Jun. 16, 2015 | ||||||
Debt Instrument, Converted Amount | $ 14,100 | ||||||
Debt Conversion #42 | |||||||
Common Stock, shares issued | 113,041,667 | ||||||
Common Stock, price per share | $ 0.00012 | ||||||
Date of Agreement | Jun. 16, 2015 | ||||||
Debt Instrument, Converted Amount | $ 13,565 | ||||||
Debt Conversion #44 | |||||||
Common Stock, shares issued | 123,583,333 | 123,583,333 | |||||
Common Stock, price per share | $ 0.00006 | $ 0.00006 | |||||
Date of Agreement | Jun. 22, 2015 | Jun. 22, 2015 | |||||
Debt Instrument, Converted Amount | $ 7,415 | $ 7,415 | |||||
Debt Conversion #45 | |||||||
Common Stock, shares issued | 247,992,413 | 247,992,413 | |||||
Common Stock, price per share | $ 0.00006 | $ 0.00006 | |||||
Date of Agreement | Jun. 22, 2015 | Jun. 22, 2015 | |||||
Debt Instrument, Converted Amount | $ 14,384 | $ 14,384 | |||||
Debt Conversion #46 | |||||||
Common Stock, shares issued | 129,200,000 | 129,200,000 | |||||
Common Stock, price per share | $ 0.00006 | $ 0.00006 | |||||
Date of Agreement | Jun. 23, 2015 | Jun. 23, 2015 | |||||
Debt Instrument, Converted Amount | $ 7,752 | $ 7,752 | |||||
Sale of Stock #3 | |||||||
Date of Issuance | Jul. 7, 2015 | Jul. 7, 2015 | |||||
Common Stock, shares issued | 161,942,326 | 161,942,326 | |||||
Common Stock, price per share | $ 0.00007 | $ 0.00007 | |||||
Common Stock, value | $ 11,335 | $ 11,336 | |||||
Sale of Stock #4 | |||||||
Date of Issuance | Jul. 15, 2015 | Jul. 15, 2015 | |||||
Common Stock, shares issued | 143,928,240 | 143,928,240 | |||||
Common Stock, price per share | $ 0.00007 | $ 0.00007 | |||||
Common Stock, value | $ 10,074 | $ 10,075 | |||||
Convertible Prom Note #21 | |||||||
Date of Agreement | May 5, 2015 | ||||||
Convertible Note | $ 68,900 | ||||||
Interest Rate | 8.00% | ||||||
Due date | May 5, 2016 | ||||||
Original Issue Discount | 780000.00% | ||||||
Convertible Prom Note #22 | |||||||
Date of Agreement | May 6, 2015 | ||||||
Convertible Note | $ 10,500 | ||||||
Interest Rate | 8.00% | ||||||
Due date | Feb. 8, 2016 | ||||||
Convertible Prom Note #23 | |||||||
Date of Agreement | May 27, 2015 | ||||||
Convertible Note | $ 16,500 | ||||||
Interest Rate | 8.00% | ||||||
Due date | May 28, 2016 | ||||||
Convertible Prom Note #24 | |||||||
Date of Agreement | Sep. 4, 2015 | ||||||
Convertible Note | $ 19,000 | ||||||
Interest Rate | 8.00% | ||||||
Due date | Jun. 4, 2016 | ||||||
2013 Stock Option Plan | |||||||
Date of Agreement | Apr. 6, 2015 | ||||||
Reserved common shares | 390,004,800 | 390,004,800 | |||||
2013 Stock Option Plan Amendment | |||||||
Date of Issuance | Apr. 16, 2015 | ||||||
Options, Granted | 204,000,250 | ||||||
Options, Term | 5 years | ||||||
Exercise Price | $ 0.0008 | ||||||
Sale of Stock #1 | |||||||
Date of Issuance | Apr. 22, 2015 | ||||||
Common Stock, shares issued | 10,037,107 | ||||||
Common Stock, price per share | $ 0.000498 | ||||||
Common Stock, value | $ 5,405 | ||||||
Sale of Stock #2 | |||||||
Date of Issuance | Jun. 25, 2015 | ||||||
Common Stock, shares issued | 154,245,477 | ||||||
Common Stock, price per share | $ 0.00007 | ||||||
Common Stock, value | $ 10,797 | ||||||
Grant of Stock | |||||||
Date of Issuance | Jun. 9, 2015 | ||||||
Common Stock, shares issued | 90,000,000 |
Subsequent Events 3M (Details N
Subsequent Events 3M (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2015 | Jun. 30, 2014 | Jun. 30, 2015 | Dec. 31, 2015 | Mar. 31, 2015 | Mar. 31, 2014 | |
Issued, Warrants | 90,000,000 | 2,483,334 | ||||
Common Stock, value | $ 220,000 | |||||
Debt Instrument, Converted Amount | $ 499,825 | $ 499,825 | $ 499,686 | $ 28,818 | ||
Reserved common shares | 390,004,800 | |||||
Due to related parties | $ 6,141 | $ 6,141 | $ 6,067 | $ 36,000 | ||
Sale of Stock #3 | ||||||
Date of Issuance | Jul. 7, 2015 | Jul. 7, 2015 | ||||
Common Stock, shares issued | 161,942,326 | 161,942,326 | ||||
Common Stock, price per share | $ 0.00007 | $ 0.00007 | ||||
Common Stock, value | $ 11,335 | $ 11,336 | ||||
Sale of Stock #4 | ||||||
Date of Issuance | Jul. 15, 2015 | Jul. 15, 2015 | ||||
Common Stock, shares issued | 143,928,240 | 143,928,240 | ||||
Common Stock, price per share | $ 0.00007 | $ 0.00007 | ||||
Common Stock, value | $ 10,074 | $ 10,075 | ||||
Convertible Prom Note #25 | ||||||
Date of Agreement | Aug. 28, 2015 | |||||
Convertible Note | $ 15,000 | |||||
Interest Rate | 8.00% | |||||
Due date | Apr. 28, 2016 |